 
Official Title:  Assessment of the Biodistribution and Safety of [18F]GTP1 in Healthy 
Japanese Subjects  
Study ID: [REMOVED] 
Document Date : Protocol  Version 3: 10-July -2020  
 
 
PROTOCOL FOR  RESEARCHI NVO LVINGHUMANS UBJECTS  
 
 
 
Title of Project : Assessment  of the Biodistribution  and Safety  of [18F]GTP1  in 
Healthy Japanese Subjects  
 
Protocol No: GN42043 
Version  No.&  Date:  V3.0 ; 09-Jul-2020 
Sponsor:  Genentech,  Inc. 
1 DNA  Way  
South San Francisco,  CA 94080-4990 U.S.A.  
United  States 
 
Principal Investigator:  , MD, PhD  
60 Temple  Street,  8th Floor  
New Haven, CT  06510 
(203)  401-4300 (24- hour pager)  
Other  Investigators:  , PA-C 

Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  4 of 47  TABLE  OF CONTENTS  
SPONSOR  APPROVAL  ............................................................................................................................................................................ 2  
INVESTIGATOR  SIGNATURE  .............................................................................................................................................................. 3  
TABLE  OF CONTENTS  ........................................................................................................................................................................... 4  
PROTOCOL  SYNOPSIS ........................................................................................................................................................................... 8  
1. Introduction  ............................................................................................................................................................................. 15 
1.1. Background  ......................................................................................................................................................................... 15 
1.2. Human Safety  and Tolerability  of [18F]GTP1  ................................................................................................ 16 
2. Study Objectives  and Endpoints  ......................................................................................................................................... 16 
3. Investigational  Plan  ...................................................................................................................................................... 17 
3.1. Study Design ....................................................................................................................................................................... 17 
3.2. Study Rationale  ................................................................................................................................................................. 18 
3.3. Risk/Benefit  for this Study .......................................................................................................................................... 19 
4. Population  ................................................................................................................................................................................. 19 
4.1. Inclusion  Criteria  .............................................................................................................................................................. 19 
4.2. Exclusion  Criteria  ............................................................................................................................................................. 20 
5. Treatment  ................................................................................................................................................................................. 21 
5.1. Investigational  Agent  ......................................................................................................................................................... 21 
5.2. Treating  the Subject  ....................................................................................................................................................... 21 
5.2.1.  Study Drug  Supply  and Storage  ...................................................................................................................... 21 
5.2.2.  Administration  of Investigational  Agent  ...................................................................................................... 22 
5.2.3.  Concomitant  Treatment  ................................................................................................................................. 22 
5.2.4.  Discontinuation  of Study Treatment  and Premature  Subject  Withdrawal ............................. 22 
5.2.5.  Study  Completion and Post -Study  Treatment  ..................................................................................... 22 
6. Visit Schedule  and Assessments ......................................................................................................................................... 23 
6.1. Study Schedule  .................................................................................................................................................................. 23 
6.1.1.  Screening  Visit  ......................................................................................................................................................... 23 
6.1.2.  Whole- body [18F]GTP1  PET  Imaging  Visit  .............................................................................................. 23 
6.1.3.  Safety  Follow -up Phone  Visit  .......................................................................................................................... 25 
6.2. Whole- body [18F]GTP1  PET Imaging Procedures  ...................................................................................... 25 
6.3. Urine  Collection for Dosimetry  Analysis  ............................................................................................................. 25 
6.4. Safety  Evaluations  ........................................................................................................................................................... 25 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  5 of 47  6.4.1.  Physical  Examination  ...................................................................................................................................... 25 
6.4.2.  Vital  Signs  ....................................................................................................................................................................... 26 
6.4.3.  Height and Weight  ................................................................................................................................................ 26 
6.4.4.  Laboratory  Evaluations  ...................................................................................................................................... 26 
6.4.4.1. Hematology  ........................................................................................................ 26 
6.4.4.2. Clinical chemistry  .............................................................................................. 26 
6.4.4.3. Urinalysis  .............................................................................................................. 26 
6.4.4.4. Serology  ................................................................................................................ 27 
6.4.4.5. Pregnancy testing  ............................................................................................. 27 
6.4.5.  Electrocardiogram  (ECG) .................................................................................................................................. 27 
7. Safety  Monitoring ....................................................................................................................................................................... 28 
7.1. Adverse  Events  ........................................................................................................................................................ 28 
7.1.1.  AE Definition ....................................................................................................................................................... 28 
7.1.2.  SAE Definition  ..................................................................................................................................................... 28 
7.1.3.  Adverse  Events  of Special  Interest Definition  ...................................................................................... 29 
7.1.4.  Cases  of Accidental  Overdose  or Medication  Error  ........................................................................ 29 
7.1.5.  Treatment  of AEs .......................................................................................................................................... 30 
7.1.6.  Relationship of AEs to the Study  Drug  ................................................................................................ .... 31 
7.2. Serious Adverse  Event  and Adverse  Event  of Special Interest  Reporting  ......................................... 31 
7.3. Methods  for Capturing  and Assessing  Safety  Parameters  ....................................................................... 32 
7.4. Procedures  for Recording  Adverse  Events  .................................................................................................. 32 
7.4.1.  Diagnosis  versus  Signs  and Symptoms .............................................................................................. 32 
7.4.2.  Adverse  Events  That  are Secondary  to Other  Events  .................................................................... 32 
7.4.3.  Deaths  .......................................................................................................................................................................... 32 
7.5. Post -Study  Adverse  Events  ................................................................................................................................ 32 
8. Data  Review  and Database Management  ....................................................................................................................... 33 
8.1. Site Monitoring .................................................................................................................................................................. 33 
8.2. Database Management  and Quality  Control ....................................................................................................... 33 
9. Data  Analysis ................................................................................................................................................................................. 33 
9.1. Subject Demographics  and Other  Baseline  Characteristics  ..................................................................... 33 
9.2. Imaging  Analysis  and Statistics ................................................................................................................................ 33 
9.3. Safety  Analysis  and Statistics ................................................................................................................................. 34 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  6 of 47 
 9.4. Sample  Size  .................................................................................................................................................................... 35 
10. Regulatory and Ethical  Considerations  .................................................................................................................... 35 
10.1. Regulatory and Ethical  Compliance  ............................................................................................................... 35 
10.2. Informed  Consent Procedures  .......................................................................................................................... 35 
10.3. Confidentiality .............................................................................................................................................................. 35 
10.4. Responsibilities  of the Investigator  and IRB .............................................................................................. 35 
11. References  ............................................................................................................................................................................... 36 
12. Appendix  1 – World  Health  Organization  Toxicity  Grading  Scale  ............................................................ 38 
13. Appendix  2 – Protocol  Summary  of Changes,  Amendment  1 ................................................................. 42 
14. Appendix  3 – Protocol  Summary  of Changes,  Amendment  2 ................................................................. 43 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  7 of 47  LIST OF ABBREVIATIONS  
Abbreviation  Definition  
Aβ Amyloid  beta 
AD Alzheimer's   disease  
ADL  Activities  of daily  living  
AE Adverse  event  
AESI  Adverse  event  of special  interest  
ALT  Alanine  transaminase  
AST Aspartate   aminotransferase  
BP Blood  pressure  
CRF  Case  report  form  
CT Computed  tomography  
CN Cognitive  normal  
ECG  Electrocardiogram  
FDA  Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
GFR  Glomerular  filtration  rate 
GI Gastrointestinal  
GMP  Good   Manufacturing  Practice  
HAT  Human  alimentary  tract 
HPLC  High -performance  liquid   chromatography  
ICH International  Conference  on Harmonization  
ICRP  International  Commission  on  Radiological  Protection  
IHC Immunohistochemistry  
IRB Institutional  Review  Board  
IV Intravenous  
MBq  Megabequerels  
mCi Milicuries  
MIRD  Medical  Internal  Radiation  Dose  
NDOB  Name  date of birth 
OLINDA  Organ  Level  Internal  Dose  Assessment  
OTC  Over  the counter  
PET Positron  emission  tomography  
PMOD  Software  for biomedical  image  quantification  
PSP Progressive   supranuclear  palsy  
QA Quality  assurance  
ROI Region  of interest  
RR Respiratory  rate 
SAE Serious  adverse  event  
SUV  Standard  uptake  value  
TAC  Time -activity  curve  
VOI Volume  of interest  
ULN  Upper  limits  of normal  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  8 of 47   
 
PROTOCOL SYNOPSIS  
TITLE  Assessment  of the Biodistribution  and Safety  of [18F]GTP1  in 
Healthy  Japanese  Subjects  
TEST  PRODUCT  [18F]GTP1  
CLINICAL  PHASE  1 
INDICATION  Alzheimer's   Disease  
TRIAL  OBJECTIVES  The overall  goal of this protocol  is to evaluate the biodistribution of 
[18F]GTP1  as a tau targeted radiopharmaceutical.  The specific  
objectives are: 
● To determine the radiation  dosimetry  of [18F]GTP1  in 
Japanese  subjects  
● To assess the safety  and tolerability  of a single dose  of 
[18F]GTP1 in Japanese  subjects  
STUDY   DESIGN  Up to 6 healthy  Japanese  subjects  (with  at least 1 male  and 1 female)  
 will  be recruited  from  the healthy  controlpopulation  by advertising  
 and community  outreach.  
 This study will  be performed in healthy  control  research participants.  
 All study  procedures  will  be conducted  at Invicro  in New Haven,  
 CT. All subjects  will  undergo  written  informed  consent  and a 
 screening  evaluation  including  baseline  clinical  laboratory  testing  
 and baseline  physicalevaluation.  
 On the day prior  to imaging  subjects  will  be admitted  for overnight  
 confinement.  On the day of imaging,  subjects  will  be asked  to 
 undergo  a single   bolus  injection  of [18F]GTP1  followed  by serial  
 whole -body  positron  emission  tomography (PET)  imaging  scans  of 
 up to 6 hours.  Immediately  following  the [18F]GTP1  administration  a 
 series   of approximately  nine whole -body  PET images  from  the 
 vertex  of the head  to the thighs  will  be obtained.  The subject  would  
 have  at least two breaks  during  the scanningsession.   An isotope  
 transmission  scan will  be performed  each  time the subject  lies on the 
 camera.  Commencingwith  radiotracer  injection,  urine  collection   will 
 be initiated.  Standard  Medical  Internal  Radiation  Dose  (MIRD)  
 assumptions  will be incorporated  in dosimetry  models  for 
 determination  of radiation  absorbed  doses  to target  organs  and 
 whole -body.  Urine   samples  collected  over the  imaging  period  will  be 
 evaluated  to measure  the excretion  of [18F]GTP1  through  the urinary  
 tract.  
 A follow -up phone  call to the subject  will  be conducted  within  4 
 days  (± 2 days)  post-injection  of [18F]GTP1  to confirm  subject  well- 
 being  and to collect  information  about  any new adverse  events  
 (AEs).  
INCLUSION/EXCLUSION  
CRITERIA  Healthy  volunteer  subjects  who are medically stable  and meet  the 
inclusion criteria and do not meet  any of the exclusion criteria  will 
be eligible   for enrollment into the study.  
Inclusion  Criteria  
● Understand  the study procedures  and agree to participate  by 
providing written  informed consent.  
● Are willing   and able to comply  with all study procedures  and 
restrictions.  WHO World   Health  Organization  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  9 of 47  ● Are males  or females  > 18 years  of age. 
● Are in good health as determined by the Investigator  based  on 
clinical  evaluations  including past medical  history, physical  
examination,  vitalsigns,   electrocardiogram  (ECG),  and 
laboratory  tests at screening  and prior  to radiopharmaceutical  
administration.  
● For women  of childbearing potential,  agreement to remain  
abstinent  (refrain from  heterosexualintercourse)  or use 
contraception,  and agreement to refrain  from  donatingeggs,  
as defined below:  
o A woman  is considered  to be of childbearing potential  
if she is postmenarchal,  has not reached  a 
postmenopausalstate (12 continuous  months of 
amenorrhea with no identified  cause  other  than 
menopause),  and is not permanently infertile  due to 
surgery  (ie,  removalof  ovaries,  fallopian  tubes,  and/or  
uterus)  or another  cause  as determined by the 
Investigator  (eg, Müllerian agenesis).  The definition of 
childbearing potentialmay  be adapted  for alignment  
with local guidelines   or regulations. 
o Women  of childbearing potentialmust  remain  abstinent  
or use contraceptive  methods  with a failure  rate of <1% 
per year during the treatment  period and for 30 days  
after  the final  dose of [18F]GTP1.  Women must  refrain  
from  donatingeggs   during this same  period. 
o Examples  of contraceptive  methods  with a failure  rate 
of <1%  per year include bilateral  tuballigation,  male  
sterilization,  hormonalcontraceptives  that inhibit  
ovulation,  hormone -releasing  intrauterine  devices,  and 
copper  intrauterine  devices . 
o The reliability   of sexualabstinence  should be evaluated  
in relation  to the duration of the clinical  trial and the 
preferred and usuallifestyle   of the subject.  Periodic  
abstinence  (eg,  calendar,  ovulation,  symptothermal,  or 
postovulation  methods)  and withdrawalare not 
adequate methods  of contraception.  If required  per local  
guidelines   or regulations, locally  recognized  adequate  
methods  of contraception  and information about the 
reliability   of abstinence  will be described  in the local  
informed consent form  
● Male  subjects  with  partners  of childbearing potentialmust  
commit  to the use of two methods  of contraception,  one of 
which is a barrier  method  (ie, condom),  for the study  duration  
and 90 days  after  the last dose.  
● Male  subjects  must  not donate  sperm  for the duration  of the 
study  and 90 days  after  the last dose.  
● Subjects  must  have  both Japanese parents  and all Japanese  
grandparents  (self-reported). 
Exclusion  Criteria  
● The subject has a clinically   significant abnormallaboratory  
value  and/or  clinically   significant unstable medical or 
psychiatric  illness.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  10 of 47  ● The subject  is currently  exposed to nicotine products  or had 
regular  nicotine exposure  within  a six-month period, to be 
verified by urine  cotinine screening.  
● History  of drug or alcohol  abuse within  12 months  prior  to 
screening,  or evidence of such abuse as indicated by the 
laboratory  assays conducted duringthe  screening  visit.  
● The subject  has evidence of clinically   significant  
gastrointestinal  (GI),  cardiovascular,  hepatic,  renal,  
hematological,  neoplastic,  endocrine,  neurological, 
immunodeficiency,  pulmonary,  or other  disorder or disease.  
● Prior  participation in other  research protocols  or clinical  care 
in the last year in addition to the radiation exposure  expected  
from  participation in this clinical  study,  such that radiation  
exposure  exceeds  the effective  dose  of 50 mSv,  which would  
be above  the acceptable annuallimit  established  by the US 
Federal Guidelines.  
● Use of any prescription drugs (except  approved forms  of birth 
control noted in Section  5.2.3), herbal supplements,  within  
four weeks  prior  to initial  dosing. 
● Use of over the counter  (OTC) medication (except  
acetaminophen),  dietary  supplements,  or vitamins,  within   two 
weeks  prior  to initial  dosing. 
● Has a known  hypersensitivity  to any component  of the 
formulation of [18F]GTP1   or related compounds.  
● Major  surgery,  or donation or loss of 400 mL or more  of 
blood within  four (4) weeks  prior  to initial  dosing, or longer  if 
required  by local regulation. 
● Have a history or presence of any significant cardiovascular,  
respiratory,  hepatic,  renal,  GI, endocrine,  or neurological  
disorders which, in the opinion of the Investigator,  are capabl e  
of altering  the absorption,  metabolism,  or elimination  of drugs  
or posing a health risk to participate  in the study.  
● History  of immunodeficiency diseases,  including a positive  
HIV test result.  
● A positive Hepatitis  B surface  antigen (HBsAg)  or Hepatitis  C 
antibody  test result.  
● Positive  pregnancy test result,  if female.  Women without  
documentation of non-childbearing potentialwill   also receive  
pregnancy testing.  
● Women  who are lactating  and breastfeeding.  
● Unsuitable veins  for repeated venipuncture.  
● Subject  is, in the opinion of the Investigator,  unsuitable  in any 
other way  to participate  in this study.  
LENGTH  OF STUDY  For each subject participating,  the duration of study participation 
will  be up to 36 days.  The completion of this study  protocol requires  
each subject  to complete  three visits:  Screening  Visit,  a single  
[18F]GTP1 Whole- body  PET Imaging Visit  and a Follow -up  Phone  
Call.  The screening  visit  will  include vital signs,   ECG  and a physical  
exam.  In addition,  each subject will  complete  clinical  assessments  
and clinical  safety  labs to ensure the subject  is medically  stable  to 
complete  the study  protocol.  The screening  procedures  will  occur  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  11 of 47   
within  30 days  of the imaging  visit.  After  subjects  have  met all study  
entry  criteria,  subjects  will  participate  in a single   [18F]GTP1   PET 
whole-body imaging session.  The Follow -up  Phone  Call for AE 
assessment  will  occur within  approximately  4 days  (± 2 days)  
following the [18F]GTP1  PET imaging. 
OUTCOMES  
 
WHOLE -BODY  
BIODISTRIBUTION  OUTCOME  
MEASURES  
 
 
 
 
 
 
 
 
SAFETY   OUTCOME   MEASURES   
 
The following parameters  will be evaluated:  
● Totalsource  organ counts  based  on individualized organ  
volumes  of interest  (VOIs)  
● Source organ uptake  and washout  with calculation of the total  
number  of disintegrations (or residence time)  using the area 
under  the time-activity  curve  divided by the injected  dose of 
radiopharmaceutical  
Radiation absorbed dose estimates  based  on the MIRD  methodology  
utilizing   urine  data and International  Commission  on Radiological  
Protection  (ICRP) GI tract kinetics  
 
Safety  will  be evaluated  by review  of AEs,  clinical  laboratory  tests,  
vital signs,  physical findings, and ECG  findings at screening  and 
intervals  throughout the imaging  visit.  A safety  Follow -up  Phone  
Call within  4 days  (± 2 days)  after  imaging will  assess for AEs and 
concomitant   medications.  
INVESTIGATIONAL    AGENT  All subjects  will  receive  a single  injection  of [18F]GTP1,  a PET 
 radioligand  selective  for tau, once  during  the course  of study  
 participation.  (See Section  5.2.2  for full details  on [18F]GTP1  
 administration.)  
PROCEDURES  SCREENI  NG:  Subject  eligibility    will  be evaluated  during screening.  
 The Whole -body  [18F]GTP1  PET Imaging  Visit  will  occur  within   30 
 days  of screening.  Screening  will  include  informed  consent,  medical  
 history  and demography  collection,  review  of medications,  review  of 
 inclusion  and exclusion  criteria,  urine  drug and alcoholtesting,  vital 
 signs,  ECG,  physical  exam,  and clinical  labs to ensure  the subject  is 
 medically  stable  to complete  the study.  All women  of childbearing  
 potentialmust  have  a negative  serum  pregnancy  test. 
 WHOLE -BODY   [18F]GTP1  PET IMAGING  VISIT:  [18F]GTP1  will 
 be synthesized  in Invicro’s  Good  Manufacturing  Practice  (GMP)  
 chemistry  laboratory  under  an approved  IND.  
 All women  of childbearing  potentia  lwill  have  a urine  pregnancy  test 
 determined  to be negative  within   24 h before  PET tracer injection.  
 Whole -body  PET imaging  will  be performed,  acquiring  an emission  
 scan for each  bed position  and an isotope  transmission  scan or 
 computed  tomography  (CT)  scan  each  time the subject  lies on the 
 camera.  Subjects  will  first receive  an isotope  transmission  scan or 
 CT scan. Then  subjects  will  receive  a bolus  intravenous  (IV) 
 administration  of [18F]GTP1.  Immediately  following  the [18F]GTP1  
 administration,  a series   of whole -body  PET images  from  the vertex  
 of the head  to the thighs  will be obtained  over a period  of up to 6 
 hours.  The subject  will  have  at least two breaks  over a six-hour 
 scanning  session.  Commencingwith   radiotracer  injection,  urine  
 collection  will  be initiated.  Standard  MIRD  assumptions  will  be 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  12 of 47   
 
 
  
 
  
 
 
 
  
 
STATISTICAL   METHODS  incorporated in dosimetry  models  for determination of radiation  
absorbed doses  to target  organs  and whole -body.  Urine samples  
collected  over the imaging period will  be evaluated  to measure  the 
excretion  of [18F]GTP1   through the urinary tract.  During the 
imaging, safety  assessments will be performed,  including ECGs,  
clinical  labs,  and vitalsign   measurements.  
If a PET scan is cancelled  due to synthesis failure  of [18F]GTP1  or 
camera problems,  injection  of [18F]GTP1  will  not occur,  and the 
scanning procedures  listed  above  will be performed on another  day 
in the same  subject.  
FOLLOW -UP  PHONE  CALL:  A follow-up phone  call for AE 
assessment  will  occur within  4 days  (± 2 days)  post-injection  
following the [18F]GTP1  PET scan imaging. 
DEMOGRAPHICS  All data for background  and demographic  variables  will be listed.  
For these  parameters,  summary  statistics  will  be provided by subject.  
Relevant  medicalhistory,  current  medical  conditions,  results  of 
laboratory screens,  and any other  relevant  information will  be listed  
by subject.  
SAFETY  Analysis  of safety  parameters  will include all vital signs,  ECG,  
clinical  laboratory  tests,  physical findings, and AE data listed  by 
subject and visit/time.  Summary  statistics  will  be provided by 
visit/time.  
IMAGING  
 
SAMPLE   SIZE  JUSTIFICATION Descriptive   statistics  will  be applied to describe biodistribution of 
[18F]GTP1 by organ.  
The sample  size for this study was determined by practical  
considerations  and is not based on statistical power  calculations.  Up 
to 6 evaluable subjects  (with  at least 1 male  and 1 female)  will 
complete  this study.  
While  the sample  size is small,  this should be adequate to determine  
biodistribution and dosimetry  calculations  of [18F]GTP1  in Japanese  
subjects.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  13 of 47   
 
Table 1: Schedule  of Assessments  
 
  
Screening  Visit   
[18F]GTP1  Whole- body  PET  Imaging Visit  Follow- up 
Phone  Call 
 
Day Within  
30 days  
of Imaging visit  
Check -in  
Within 30 days of screening  4 days  
(± 2 days)  
post-injection  
Time  in relation  to 
radioligand injection   Day prior  
to PET  
Imaging  Pre- 
injection  Imaging  
period   
Post scan   
Inclusion/Exclusion  
Criteria  X  X    
Informed Consent  X      
Medical History  X      
Demography X      
Physical   Examination  X X1     
Height  and Weight  
Measurement2 X  X    
Vital  Signs3 X  X X X  
ECG4 X  X X X  
Hematology,  Blood  
Chemistry,  Serology   & 
Urinalysis5  
X   
X   
X  
Serum  Pregnancy  Test 
(if  applicable)6  
X      
Urine  Pregnancy Test 
(if  applicable)6    
X    
Urine Drug,  Alcohol,  
and Cotinine Screen   
X  
X     
[18F]GTP1  Injection7   X    
Whole-body PET 
Imaging     X   
Urine  Collection8    X X  
Adverse Events  X X X X X X 
Concomitant  
Medications  X X X   X 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  14 of 47   
 
1 The physicalwill   be symptom -directed.  
2 Height  will  only be measured  during screening.  
3 Vital  signs  (systolic   and diastolic  blood pressure  [BP],  respiratory  rate, and pulse rate)  will  be obtained  after  at least 5 
minutes  of rest in the supine position during screening  and at the Whole -body  [18F]GTP1  PET Imaging Visit  at the 
following timepoints:  pre- injection  and approximately 20, 50, 80, and 120 minutes  following injection. Oral body  
temperature will be obtained during screening  and at the Whole -body [18F]GTP1  PET Imaging  Visit  at the following  
timepoints:  pre- injection  and at the completion of imaging. 
4 Electrocardiogram  (ECG)  will  be obtained  during screening and at the Whole- body  [18F]GTP1  PET Imaging  Visit  at the 
following timepoints:  pre-injection, approximately 25 and 45 minutes  following  injection, and at the completion of the 
imaging session. 
5  Safety  labs (hematology,  blood chemistry  and urinalysis)  will  be obtained  during screening  and at the Whole- body 
[18F]GTP1  PET Imaging  Visit  at the following timepoints:  pre-injection  and at the completion of imaging. Serology   (HIV  
and Hepatitis  B & C testing)  will  be performed  at screening  only.  Hematology  will  include hemoglobin,  hematocrit,  red 
blood cell count,  white  blood cell count with differential  (absolute  count  and percentage),  and platelet  count.  Blood 
chemistry  assessments will  inc lude albumin,  albumin/globulin ratio (calculated),  alkaline  phosphatase,  alanine  
transaminase  (ALT), aspartate aminotransferase (AST), bun/creatinine  ratio (calculated),  calcium,  carbon  dioxide, 
chloride, creatinine with glomerular  filtration  rate (GFR)  estimated,  globulin (calculated),  glucose, potassium,  sodium,  
totalbilirubin,  totalprotein,  urea nitrogen. Urinalysis  will include leukocytes,  nitrites,  urobilinogen, protein, pH, blood  
(erythrocytes),  specific gravity, ketone,  bilirubin   and glucose  
6 For women  of childbearing potential,  a serum  pregnancy test will  be performed during screening.  Urine pregnancy test 
will  be done  at the Whole-body [18F]GTP1  PET Imaging Visit.   The test will  occur  within  24 hours  prior  to the injection   
of [18F]GTP1  injection. Women  without documentation of non- childbearingpotentialwill   also receive pregnancy testing.  
7  Approximately,  but not exceeding,  370 MBq  (10 mCi)  of [18F]GTP1  will  be injected IV by bolus  injection.  
8  Urine samples  will  be collected  over the imaging period and at scan completion to measure  the excretion  of [18F]GTP1  
through the urinary tract.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  15 of 47   
1. INTRODUCTION  
1.1. Background  
Molecular  imaging biomarkers  have the potential  to play a key diagnostic role in tauopathies.  
Tau protein  has been identified  as one of the key pathological  features of Alzheimer’s  disease 
(AD)  (Wood et  al., 1986; Grundke  et al., 1986; Kosik et al., 1986). Given  the role of tau protein  
in the pathology of AD and other  non-AD tauopathies, expanding neuroimaging biomarkers  to 
include  a tau radiotracer  is a logical  next target  offering the  potential to improve  our 
understanding of the pathological  process in AD and other  tauopathies. Tau  is the primary  protein  
composing neurofibrillary  tangles  and unlike  amyloid β (Αβ)  deposition, post -mortem         
studies  have shown that neurofibrillary  tangle  density correlates  with neurodegeneration and 
cognitive  impairment ( Duyckaerts et al., 1987, 1990; Delaere et al., 1989; Arriagada  et al., 1992;  
McLean  et al., 1999).  Thus,  a positron emission  tomography (PET)  imaging agent  that binds  to 
aggregated tau  has the potential to serve  as a biomarker  for disease severity  or neurodegeneration 
and may be useful for monitoring disease progression  in therapeutic  trials.  
Development  of a tau radiotracer  would provide a useful tool to evaluate tau specific therapeutics 
for both AD and non- AD tauopathies. Tau  hyperphosphorylation occurs  as a result  of an 
imbalance  of the kinase  and phosphatase  activities,  which  normally tightly  regulate  its 
phosphorylation. In addition  to this pathogenic  hyperphosphorylation, tau dissociates from  
microtubules  and self -aggregates to form  insoluble  oligomers  ultimately  progressing to the 
macroscopic  tangles  evident in AD and non- AD tauopathies. Potential interventions  for 
tauopathies might  include  the inhibition of kinases responsible  for hyperphosphorylation and 
many  candidate  kinases are currently  under  investigation  (Churcher, 2006).  The search  for t hese 
treatments  is paralleled  by a pursuit  for a means  to identify  those  patients  best suited  for the 
therapy and methods  to non-invasively determine  the efficacy  of treatments with the potential to 
reduce tau. 
Until  recently,  post -mortem examination of brain tissues was the only means  available  for 
directly  evaluating the changes  occurring  in the brain  in AD and non- AD tauopathies. In  the last 
decade,  the development  of highly specific techniques  for imaging  the brain  in AD and other  
dementias has expanded  our ability  to measure the process of the disease over time in a living  
individual. Briefly,  these techniques  involve  intravenous  (IV) administration  of radioactively - 
labeled  compounds which  bind to selective target  sites in brain. PET is able to detect  the spatial  
distribution  of the radioactive  compound  in the brain  and can  be used as an objective, sensitive,  
and accurate method to  quantify the concentration of the targets  site in different  brain  regions.  
Using  these PET techniques,  Aβ aggregates have been successfully  imaged  in several  studies  in 
AD patients using high affinity  C-11 and 18F-labeled PET tracers (PIB  and florbetapir,  AV-1) 
(Klunk et  al., 2004ab;  Clark  et al, 2011; Hyman  2012).  Now there  are mu ltiple  studies  
comparing  amyloid PET scans to histopathologic  assessment  that support  the relationship  
between  PET amyloid  imaging results  and cortical  neuritic  plaque density ( Stephens  2014;  
Ruiqig N 2013; Leinonen, 2008; Sojkova, 2011).  
The ability  to image  brain  amyloid has offered  an important  advance for the diagnosis  of 
neurodegenerative  conditions. In  contrast  to Aβ neuritic  plaques,  the density  and distribution of 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  16 of 47  phosphorylated tau, aggregated in  neurofibrillary  tangles,  increases  with AD- related  cognitive  
impairment  and correlates  with neurodegeneration ( Dickson et  al., 1997; Duyckaerts et al., 
1987).  Thus,  the development  of PET imaging agent  that binds to aggregated tau  offers  the 
potential to improve  our understanding of the molecular  mechanism  of neurofibrillary  
degeneration and is critical  to developing a rational therapeutic  treatment  of AD and related  
tauopathies. 
[18F]GTP1  (also known as [18F]G02941054, and referred  to as [18F]MNI -798 in some  previous  
clinical  studies) has been developed as a positron emitting  radiopharmaceutical  for in vivo 
imaging of tau protein  aggregates.  In a cross- sectional  study  of cognitively normal  and 
prodromal  to moderate AD patients,  [18F]GTP1  exhibited good brain  penetration  and rapid  
washout, excellent  test-retest  reproducibility,  and favorable  radiation  dosimetry  profile.  In 
general,  SUVR values  increased  with disease severity  and differentiated  between  AD and 
cognitive  normal  (CN)  cohorts and between  brain  regions  predicted  to contain  high versus low 
tau burden,  supporting the  use of [18F]GTP1  PET imaging  as a biomarker  of tau pathology in  AD 
(Bohórquez  et al.). The study drug is referred  to as [18F]GTP1 throughout the protocol and 
informed  consent  documents  given that the radiopharmaceutical  bears the label of [18F]GTP1  and 
that the names  are synonymous.  
 
1.2. Human  Safety  and Tolerability  of [18F]GTP1  
As of 1 February 2019, [18F]GTP1  has been evaluated in three  completed  clinical  studies (e0040, 
e0048, and e0049)  and is being evaluated in five ongoing studies:  Study GN30009, Substudy 
WN29922/WN39658, Study GN39763, Substudy  BN29552/BN29553, and Study  GN40040. All 
studies  in the clinical  development  program  have been conducted in accordance with the 
principles  of Good Clinical Practice.  A total of 23 healthy volunteers, 470 patients  with AD,  and 
3 patients  with progressive  supranuclear  palsy (PSP)  have been exposed to at least one dose of 
[18F]GTP1,  and there  have been a total of 702 doses in total across all studies.  Two of the 470 
patients  with AD were  enrolled  in more  than one study  (in Study e0048 and in  Study GN30009). 
[18F]GTP1  was found to be generally  well tolerated.  As of 1 February 2019, no deaths  or adverse 
events (AEs)  of special  interest  were  reported. One serious adverse event  (SAE)  was reported in  
Study GN30009:  a Grade  3 urinary  tract infection, reported in  a - year-old  patient  with 
moderate AD; the SAE  was assessed  as not related  to study drug. One -year-old  patient  
with prodromal  AD discontinued the study  due to a non-serious moderate headache and non- 
serious cervical  neck pain  4 days  after  a baseline  [18F]GTP1  PET scan;  both events were   
assessed  as not related  to study  drug. 
 
2. STUDY OBJECTIVES AND ENDPOINTS  
The overall  goal of this protocol is to evaluate the biodistribution  of [18F]GTP1 as a tau targeted  
radiopharmaceutical.  

Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  17 of 47   
Objectives  Endpoints  
To determine  the radiation  dosimetry  of 
[18F]GTP1  in Japanese subjects  ● Total source organ counts  based  on 
individualized organ  volumes  of interest  
(VOIs) 
● Source  organ  uptake  and washout with  
calculation  of total number  of 
disintegrations  (or residence time, or kinetic  
values)  using  the area under  the time- 
activity curve  divided by the injected  dose 
of radiopharmaceutical  
● Radiation  absorbed dose estimates  based  on 
the MIRD methodology  utilizing  urine  data 
and International  Commission  on 
Radiological  Protection  (ICRP)  
gastrointestinal (GI) tract kinetics  
To assess  the safety  and tolerability  of a single  
dose  of [18F]GTP1  in healthy  Japanese subjects  Safety  will be evaluated  by review  of: 
● AEs 
● Clinical laboratory tests 
● Vital  signs  
● Physical findings  
● ECG findings  
 
3. INVESTIGATIONAL PLAN 
3.1. Study Design  
This is an open- label  study  to evaluate the whole- body biodistribution of [18F]GTP1  in up to  6 
evaluable  healthy Japanese subjects (with at least 1 male  and 1 female)  to determine  dosimetry  
for future  studies. Subjects  will be recruited  by Invicro  from  the healthy population by 
advertising  and community outreach. This study  protocol  requires  each subject  to complete the 
following visits: Screening  Visit,  Whole -body [18F]GTP1  PET Imaging Visit,  and a Follow -up 
Phone Call. Screening  evaluations  will occur  within 30 days  of the Whole -body [18F]GTP1 PET 
Imaging Visit and may occur  over multiple  days. Screening  procedures  will include  signing of 
the informed  consent  form,  review  of inclusion  and exclusion criteria,  collection  of medical  
history  and medication  information, collection  of demography information, physical  
examination,  height  and weight  measurement,  vital signs  (respiratory  rate, pulse  rate, blood 
pressure  [BP] and oral body temperature),  laboratory tests (hematology, blood chemistry, and 
urinalysis),  ECG,  serum  pregnancy test  (if applicable),  and drug and alcohol  screening.  
Assessments  will determine  if the subject  is medically  stable to complete the study protocol and 
meets the eligibility  criteria.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  18 of 47  Subjects  will be confined on the  day prior to [18F]GTP1  imaging in the overnight  confinement  
unit. On  the day of check -in, the subjects will receive a symptom- directed physical  assessment,  
drug and alcohol  screening, and review  of concomitant  medications.  
The following day,  there  will be a review  of inclusion  and exclusion  criteria,  a weight  
measurement,  a review  of concomitant  medications,  and a urine  pregnancy test (if applicable)  to 
assess if the subject  still meets the eligibility  criteria.  For the [18F]GTP1  imaging  session,  a 
catheter  will be placed  for IV administration  of [18F]GTP1.  Subjects will receive an IV bolus  
injection  of [18F]GTP1  (see Section  5.2.2 for full details  on [18F]GTP1  administration).  
Immediately  following the  [18F]GTP1  administration,  a series  of whole -body PET images from  
the vertex  of the head to the thighs will be obtained over  a period of up to  6 hours. The subject  
will have at least two breaks  over a six-hour scanning session.  An isotope  transmission  scan or 
computed tomography (CT)  scan will be performed  each time  the subject  lies on the camera.  
Commencing  with radiotracer  injection, urine  collection  will be initiated. Standard  MIRD  
assumptions  will be incorporated  in dosimetry models  for determination  of radiation  absorbed 
doses  to target  organs  and whole -body. Urine samples  collected  over the imaging period and at  
the completion of imaging  will be evaluated  to measure the excretion  of [18F]GTP1  through the  
urinary  tract.  Safety  assessments (ie, vital signs, clinical  laboratory assessments,  and ECGs)  will 
be performed during the imaging visit.  The subjects  will be discharged after  all assessments are 
complete.  
AEs will be assessed  from  screening  until the subject  discontinues study  participation.  An 
Investigator or designee will evaluate the subject  for AEs prior to discharge  from  the imaging 
center  on the  day of the Whole -body  [18F]GTP1  PET Imaging  Visit.  Subjects  who experience  an 
AE will not be discharged from  the imaging center  until the event  has resolved or stabilized.  
A Follow -up Phone Call to the subject  will be conducted within  4 days  (± 2 days)  post-inj ection 
of [18F]GTP1,  to confirm  subject  well-being and to  collect  information about  any new  AEs.  
 
3.2. Study Rationale  
This is an open- label  study  to evaluate the reliability  of using microdoses (less than 10 µg) of 
radiotracer  [18F]GTP1 for the evaluation of the whole- body  biodistribution  of the tracer  in 6 
healthy Japanese subjects (with  at least 1 male  and 1 female).  Evaluating a small  number  of 
healthy subjects is standard to develop dosimetry calculations and to  evaluate safety  and 
tolerability.  While  [18F]GTP1 dosimetry  studies  and safety studies have been performed in 
healthy subject  populations, the dosimetry  and safety  of [18F]GTP1 have not been specifically  
studied  in Japanese subjects.  
The development  of a PET tracer  for tau offers  the possibility to utilize  such an agent  toward  the 
development  of investigational  therapies  and the  further  understanding  of the pathophysiology of 
AD and other  tauopathies and could therefore  provide a societal  benefit  by accelerating  the 
development  of new treatments  for AD and other  tauopathies. 
There is no direct  benef it to subjects who participate  in this protocol. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  19 of 47  3.3. Risk/Benefit for this Study  
There may be unknown risks to [18F]GTP1, but given that the investigational agent  will be 
administered  as a single  microdose,  the risk for a pharmacological  effect  is considered  to be 
minimal.  The potential benefit  of the agent  is the availability  of a radiotracer  targeting  tau protein  
offering the  possibility  of improvement  in diagnostic accuracy  of AD and for  measuring  changes  
in tau with  novel  AD therapies.  The primary  risk associated  with  this study  involves  radiation  
exposure. The tracer  doses used in this study  and the  experience of the Investigators  in the 
execution of PET studies  in humans  in addition  to the potential benefit  of the [18F]GTP1  ligand  
for diagnostic uses make  the relative  risk/benefit ratio quite favorable. 
 
4. POPULATION  
The Investigator will ensure  that all subjects  being considered  for the study  meet  the eligibility  
criteria.  Subject  selection  is to be established  by checking through all  inclusion/exclusion criteria  
at screening  and at  the imaging visit.  A relevant  record  (eg, checklist)  will be stored with  the 
source  documentation at the study site. 
The study population will  be composed  of healthy Japanese subjects (with at least 1 male  and 1 
female).  Subjects will be enrolled until up to  6 evaluable  subjects  complete the study.  
 
4.1. Inclusion Criteria  
Subjects  eligible  for inclusion in this study only if they meet  all the following criteria: 
● Understand the study  procedures  and agree to participate  by providing written  informed  
consent. 
● Are willing  and able  to comply  with all study  procedures  and restrictions.  
● Are males or females > 18 years of age. 
● Are in good health  as determined by the  Investigator based  on clinical  evaluations  including 
past medical  history, physical  examination, vital signs, ECG,  and laboratory  tests at 
screening  and prior to radiopharmaceutical  administration.  
● For women  of childbearing potential,  agreement  to remain  abstinent  (refrain  from  
heterosexual  intercourse)  or use contraception, and agreement  to refrain  from  donating  eggs, 
as defined  below:  
o A woman  is considered  to be of childbearing  potential if she is postmenarchal, has not 
reached  a postmenopausal  state (12 continuous  months of amenorrhea  with no identified 
cause other  than menopause), and is  not permanently infertile due to surgery (ie, 
removal  of ovaries,  fallopian  tubes, and/or uterus)  or another cause as determined by the  
Investigator (eg, Müllerian  agenesis).  The definition of childbearing  potential may be 
adapted  for alignment  with local  guidelines  or regulations.  
o Women  of childbearing potential must  remain  abstinent  or use contraceptive  methods  
with a failure rate of <1%  per year during the treatment period  and for  30 days  after the 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  20 of 47  final dose of [18F]GTP1. Women  must  refrain  from donating eggs during this same 
period. 
o Examples  of contraceptive methods  with a failure  rate of <1%  per year include  bilateral  
tubal  ligation,  male sterilization,  hormonal  contraceptives that inhibit  ovulation, 
hormone -releasing  intrauterine  devices,  and copper  intrauterine  devices.  
o The reliability  of sexual  abstinence should be evaluated in  relation  to the duration of the 
clinical  trial and the  preferred  and usual  lifestyle  of the subject. Periodic  abstinence (eg, 
calendar,  ovulation, symptothermal, or postovulation methods)  and withdrawal  are not 
adequate  methods  of contraception. If required per local guidelines  or regulations,  
locally  recognized adequate  methods of contraception and information  about  the 
reliability  of abstinence will be described in the local informed  consent  form.  
● Male subjects with partners  of childbearing potential must  commit  to the use of two methods  
of contraception, one of which  is a barrier method (ie,  condom), for  the study duration  and 90 
days  after  the last dose. 
● Male subjects must  not donate  sperm  for the duration of the study  and for  90 days  after  the 
last dose. 
● Subjects  must  have both Japanese parents  and all  Japanese grandparents (self-reported).  
4.2. Exclusion  Criteria  
Subjects  fulfilling  any of the following  criteria  are not eligible  for inclusion  in this study:  
● The subject  has a c linically  significant  abnormal  laboratory value  and/or clinically  significant  
unstable  medical  or psychiatric  illness.  
● The subject  is current ly exposed to nicotine  products or had regular  nicotine  exposure within  
a six-month period, to  be verified  by urine  cotinine  screening.  
● History  of drug or  alcohol  abuse  within 12 months prior to screening,  or evidence of such 
abuse as indicated  by the laboratory  assays conducted during the screening  visit.  
● The subject  has evidence of clinically  significant  GI, cardiovascular,  hepatic,  renal,  
hematological, neoplastic,  endocrine, neurological, immunodeficiency, pulmonary, or other  
disorder  or disease.  
● Prior participation  in other research  protocols  or clinical  care in the last year in addition  to 
the radiation  exposure  expected  from  participation  in this clinical  study,  such that radiation  
exposure  exceeds the effective dose of 50 mSv,  which  would be above  the acceptable annual  
limit established  by the  US Federal  Guidelines. 
● Use of any prescription  drugs  (except  approved forms  of birth control noted in Section  5.2.3),  
herbal  supplements, within four weeks prior to initial dosing. 
● Use of over the counter (OTC)  medication  (except  acetaminophen),  dietary supplements, or 
vitamins, within two  weeks prior to initial dosing. 
● Has a known hypersensitivity  to any component  of the formulation  of [18F]GTP1 or related  
compounds. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  21 of 47  ● Major  surgery, or donation or loss of 400 mL  or more  of blood within four (4) weeks  prior to 
initial dosing, or longer  if required by local  regulation. 
● Have  a history  or presence of any significant cardiovascular,  respiratory, hepatic,  renal,  GI, 
endocrine, or neurological  disorders which, in  the opinion of the Investigator, are capable  of 
altering  the absorption, metabolism,  or elimination  of drugs or posing a health  risk to 
participate  in the study.  
● History  of immunodeficiency diseases,  including a positive  HIV test result.  
● A positive Hepatitis  B surface antigen (HBsAg)  or Hepatitis  C antibody test result.  
● Positive  pregnancy test  result,  if female.  Women  without  documentation of non-childbearing  
potential will also receive pregnancy  testing.  
● Women  who are lactating  and breastfeeding.  
● Unsuitable  veins  for repeated venipuncture. 
● Subject  is, in the opinion of the Investigator,  unsuitable  in any other  way to participate  in this 
study. 
 
5. TREATMENT  
5.1. Investigational  Agent  
[18F]GTP1is  a clear solution formulated for  IV injection.  [18F]GTP1  is formulated  in 0.9% 
sodium chloride  injection  containing ethanol and sodium ascorbate.  The final product  bears a 
label with the following items: total activity  (mCi),  volume  (mL),  strength (mCi/mL),  calibration  
date and time,  batch number, study ID and shelf  life. [18F]GTP1  will be stored  at ambient  
temperature  in its original  container.  
[18F]GTP1  is supplied as a sterile  non-pyrogenic  solution in sterile  borosilicate  glass  vials with 
gray butyl  septa  and aluminum  ring seals.  The vial is contained within an outer  lead or tungsten 
shield  (“pig”)  to protect  from  γ radiation.  
5.2. Treating  the Subject  
 
5.2.1. Study  Drug  Supply  and Storage  
The investigational agent, the radiopharmaceutical  [18F]GTP1, will be produced in  the Invicro  
radiochemistry  facility  at 60 Temple  Street,  New Haven, CT.  Quality  control testing includes  
strength by gamma  assay,  radiochemical  purity  and identity  (HPLC),  drug  mass and total 
impurity quantification, pH,  visual  inspection, pyrogenicity and sterility  by compendial  tests.  
The final drug product  is provided as a clear,  sterile  solution in a 30 mL  glass vial. The vial is 
contained within a  secondary  lead or tungsten radiation  shield  and may be stored upright  at 
ambient  temperature  and humidity until administration.  The investigational  agent  must  be used 
within the expiration  time (10 hours).  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  22 of 47  5.2.2. Administration  of Investigational  Agent  
Study center  personnel  will administer [18F]GTP1 IV as a bolus  injection.  Prior to PET imaging, 
subjects will have an IV catheter  (for radiotracer  administration) inserted  according to standard  
clinical  practice.   Each  subject  will receive a single  injection of [18F]GTP1.  The radioligand, 
[18F]GTP1, will be injected  IV at a dose of not more  than 370 MBq (≤ 10 mCi),  with a maximum  
drug mass dose of 10 µg and maximum volume  of 10 mL. The injection  will occur  as a bolus  
followed by a 10 mL saline  flush. Qualified  study  staff will accompany  subjects during PET 
imaging procedures.  
 
5.2.3. Concomitant Treatment  
Use of any prescription  drugs, herbal  supplements, within four (4) weeks prior to initial  dosing, 
and/or OTC medication, dietary  supplements  (vitamins  included)  within two (2) weeks prior to 
initial dosing is  prohibited. Approved forms  of prescription  birth control (hormonal  
contraceptives,  hormone -releasing  intrauterine  devices,  and copper  intrauterine  devices)  are not 
prohibited and will be documented as  a concomitant  medication. If needed (ie, an incidental and 
limited  need),  acetaminophen  is acceptable,  but must  be documented as a concomitant  
medication/significant  non-drug therapy. 
5.2.4. Discontinuation  of Study  Treatment  and Premature Subject  Withdrawal  
The study will be stopped, and no further  dosing will occur, pending a full safety  review  if one or 
more  study  drug related  SAEs  are reported. If  a subject  withdraws  or discontinues the study  for 
any reason,  the subject  will be replaced  until there  are up to (with at least 1 male  and 1 female)  
evaluable  subjects.  
Subjects  may volunta rily withdraw  from  the study  for any reason  at any time.  They  may be 
considered withdrawn  if they state an intention to withdraw,  fail to return  for visits,  or become  
lost to follow -up for  any other reason.  
If premature  withdrawal occurs  for any reason,  the Investigator must  make  every  effort  to 
determine  the primary  reason  for a subject’s premature  withdrawal  from  the study  and document 
this information in the study  source.  
Subjects  may develop AEs or abnormalities  in vital signs, ECG,  physical  examination, or 
laboratory  determinations  during their  participation  in the study. If these  occur, the Investigator 
may discontinue a subject  from  the study  if, in his/her  clinical  judgment, continued participation  
would result  in undue  risk or further worsening of the condition. 
For subjects who are lost to follow-up (ie,  those subjects whose status  is unclear  because they 
fail to appear  for study  visits  without  stating  an intention to  withdraw),  the Investigator should 
show  due diligence  by documenting attempts  to contact  the subject,  eg, dates  of telephone  calls,  
registered  letters,  or other attempts to communicate.  
 
5.2.5. Study  Completion  and Post-Study  Treatment  
The study will be complete when  the last subject  (including replacement  subjects)  completes the 
final phone visit.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  23 of 47  The Investigator must  provide follow-up evaluation by phone or by clinic  visit for all subjects  
who are prematurely withdrawn  from the study  or must  refer them  for appropriate  ongoing care.  
 
6. VISIT  SCHEDULE AND  ASSESSMENTS 
The full assessment  schedule  is presented just  before Section  1 (Introduction) of this protocol. 
 
6.1. Study Schedule  
Study procedures  will be performed  at three  visits: the Screening  Visit  (may  be performed  on 
more  than one day), Whole -body [18F]GTP1  PET Imaging Visit (including  check -in procedures),  
and a Follow -up Phone Call. 
 
6.1.1. Screening  Visit  
Screening  evaluations  will occur  within 30 days  prior to the imaging visit.  Before  any of the 
screening  evaluations  are performed  for the specific purpose of this study,  the subject  must  
provide informed  consent  for this study  in compliance  with Good Clinical  Practice (GCP)  and 
IRB requirements.  Collection  of AE data will begin after  the informed consent  is signed and will 
continue  until the subject  discontinues study  participation.  The screening  procedures  listed  below  
will be performed  and documented to assess whether  a subject  meets inclusion/exclusion criteria:  
● Inclusion and exclusion criteria  will be reviewed.  
● A medical  history will be taken, and demographics  will be recorded.  
● Concomitant  medicati on information  will be obtained.  
● Vital signs  will be taken after  at least 5 minutes  of rest in the sitting  position, including 
systolic  and diastolic  BP, pulse  rate, respiratory  rate (RR),  and oral  temperature.  
● A complete physical  examination  will be performed, including  height  and weight. Rectal,  
breast  and genital  examinations  are not required as part of this examination. 
● A 12-lead ECG will be performed. 
● Blood samples will be collected  for clinical  chemistry, hematology, HIV,  and Hepatitis  B and 
C evaluations.  
● Urine sample  will be collected  for urinalysis,  drugs  of abuse, alcohol, and cotinine  screen.  
● Serum  pregnancy test,  if female  of childbearing  potential.  
6.1.2. Whole -body  [18F]GTP1  PET Imaging  Visit  
AEs will be continuously monitored  during the Whole -body  [18F]GTP1 PET Imaging  Visit.  All 
eligible  subjects will be admitted  to the overnight  confinement  unit on the  day prior  to the 
Whole -body  [18F]GTP1 PET Imaging  Visit,  which  will occur  within  30 days  of screening. Upon 
check -in, the following procedures  will be performed: 
● Urine drug, alcohol, and cotinine  screening  will be performed. 
● A symptom- directed physical  will be performed. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  24 of 47  ● Concomitant  medications will be recorded.  
On the day of imaging, procedures  will be performed  to ensure  that the subject  still meets the 
eligibility  criteria.  Prior  to imaging the following procedures  will be performed: 
● Review of inclusion and exclusion  criteria.  
● Subject  weight  measurement  will be obtained.  
● Concomitant  medications will be recorded.  
● Vital signs  will be taken just  prior  to imaging (after  at least 5 minutes  of rest in the sitting  
position), including systolic  and diastolic  BP, pulse  rate, RR, and oral temperature.  
● A 12-lead ECG will be performed. 
● Blood samples will be collected  for clinical  chemistry  and hematology, and a urine  sample  
will be collected  for urinalysis. 
● Urine pregnancy test, if female  of childbearing  potential (which  must  be confirmed  as 
negative  within  24 hours  prior  to [18F]GTP1 injection).  
The subject  will have a venous  catheter  placed  in the forearm  for administration  of [18F]GTP1,  
and the  subject  will lie supine  on the  camera in preparation  for [18F]GTP1  administration.  
[18F]GTP1  will be administered  as a bolus  IV injection  (See Section  5.2.2 for full details on 
[18F]GTP1  administration.).  Immediately  following [18F]GTP1  administration,  PET acquisition  
will begin. PET scans will be acquired over approximately  6 hours, and the  subject  may have 
two breaks  during the scanning period. A CT scan will be performed  each time  the subject  lies 
on the  camera.  The following procedures  will be performed during PET imaging:  
● Vital signs  will be  taken, including systolic  and diastolic  BP, pulse  rate, and RR (taken  after  
at least 5 minutes  of rest in the sitting  position), approximately 20, 50, 80, and 120 minutes  
post-injection  of [18F]GTP1.  
● ECG will be taken approximately 25 and 45 minutes  post-injection  of [18F]GTP1, and at  
completion  of PET imaging. 
● The subject  will be asked  to void during scheduled breaks  in the imaging  session.  Urine will 
be collected  over a period of up to  6 hours  throughout the imaging  visit for dosimetry  
analysis.  
At the completion  of imaging  the following procedures  will be performed: 
● Vital signs  will be taken, including systolic  and diastolic  BP, pulse  rate, RR, and oral  body 
temperature  (taken  after  at least 5 minutes  of rest in the sitting  position).  
● ECG will be taken. 
● Blood samples will be collected  for clinical  chemistry  and hematology, and a urine  sample 
will be collected  for urinalysis. 
● Urine will be collected  for dosimetry  analysis.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  25 of 47  The subject  will be discharged  after all assessments are complete and the subject  has been 
evaluated for AEs.  Subjects  who experience  an AE will not be discharged until the event  has 
resolved or stabilized.  
 
6.1.3. Safety Follow -up Phone  Visit  
Subjects  will be contacted  by phone approximately 4 days  (± 2 days)  after the imaging  visit,  for 
evaluation of AEs and concomitant  medications.  The subject  will be interviewed  to determine  if 
any new  AEs occurred or if there  have been any new  concomitant  medications  administered.  If 
new medical  symptoms  have occurred  that require  further  assessment  the subject  will be asked  to 
return  to the research  clinic  for further  evaluation.  
 
6.2. Whole -body [18F]GTP1  PET Imaging Procedures  
Whole -body  PET imaging  will be performed  on a Biograph 6 PET/CT camera acquiring an 
emission  scan for each bed position and a CT scan will be performed  each time  the subject  lies 
on the  camera.  Subjects will then receive a bolus  IV administration  of [18F]GTP1 (See Section  
5.2.2 for full details on [18F]GTP1  administration.).  Immediately  following  the [18F]GTP1  
administration  a series  of whole -body PET images  from  the vertex  of the head to  the thighs will 
be obtained over  a period  of up to  6 hours. The subject  will have at least two breaks  over a six- 
hour scanning  session.  
 
6.3. Urine Collection for Dosimetry  Analysis  
Commencing  with radiotracer  injection, urine  collection  will be initiated. Standard  MIRD  
assumptions  will be incorporated  in dosimetry models  for determination  of radiation  absorbed 
doses  to target  organs  and whole -body. Urine samples  collected  over the imaging period will be 
evaluated to measure the excretion  of [18F]GTP1  through the  urinary  tract.  
 
6.4. Safety Evaluations  
The Investigators  will be responsible  for monitoring the safety  of the subjects that enter  this trial. 
Safety  will be evaluated by assessment  of AEs,  clinical  safety  laboratory  tests,  ECG,  and vital  
signs  as outlined in the Schedule of Assessments.  
 
6.4.1. Physical  Examination  
A complete physical  examination  will include  the examination  of general  appearance,  skin, neck  
(including thyroid),  eyes,  ears, nose,  throat,  lungs,  heart,  abdomen, back, extremities,  
musculoskeletal,  and neurological.  Rectal,  breast  and genital  examinations  are not required  as 
part of this examination. A symptom- directed  exam  will be completed  upon admission  for the 
Whole -body  [18F]GTP1 Imaging Visit; if the subject  has new symptoms,  only the  systems 
relevant  to the symptoms  will be examined.  
Information  for all physical  examinations  must  be included in  the source  documentation at the 
study  site and will be recorded. Significant  findings  that are present  prior  to injection  of 
[18F]GTP1  will be included in the medical  history  in the subject's source  documents. Significant  
findings  made  after injection  of [18F]GTP1,  which  meet  the definition  of an AE must  be recorded  
as an AE. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  26 of 47  6.4.2. Vital Signs  
Vital signs  include  systolic  and diastolic  BP, RR, oral temperature and pulse  rate. Vital signs  will 
be obtained during screening  and at  the Whole -body [18F]GTP1  PET Imaging Visit,  as outlined 
in the Schedule of Assessments.  Temperature  will not be taken while the subject  is actively  
undergoing imaging, to avoid any head movement. 
 
6.4.3. Height and Weight  
Height  and body weight  (in indoor  clothing)  will be measured  at screening,  and weight  will be 
recorded again at the Whole -body [18F]GTP1  PET Imaging Visit.  
6.4.4. Laboratory  Evaluations  
In the case where  a laboratory  value  is outside the reference range at screening, a decision 
regarding whether  the result is of clinical  significance or not shall be made  by the Investigator  
and shall  be based,  in part, upon the  nature  and degree of the observed abnormality.  The 
assessment  may be repeated once (for the purpose of inclusion)  and in  any case,  prior  to 
enrollment/randomization,  to rule out laboratory  error.  
In all cases,  the Investigator will document the clinical  considerations  (ie, result  was/was not 
clinically  significant and/or medically  relevant)  in allowing  or disallowing the subject  to 
continue  in the study. 
Clinically  relevant  deviations of laboratory  test results  will be reported as an AE, if the criteria  
are met. Repeated  evaluations  are mandatory until normalization of the result(s) or until the 
change  is no longer  clinically  relevant.  
 
6.4.4.1. Hematology  
Hemoglobin, hematocrit,  red blood cell count, white  blood cell count  with differential  (absolute  
count  and percentage),  and platelet  count  will be measured.  
 
6.4.4.2. Clinical  chemistry  
A standard  chemistry  panel  will be obtained including electrolytes,  liver function  tests and 
analytes to measure renal  function, including albumin, albumin/globulin  ratio (calculated),  
alkaline  phosphatase, ALT,  AST,  bun/creatinine  ratio (calculated),  calcium,  carbon  dioxide, 
chloride, creatinine  with GFR estimated, globul in (calculated),  glucose, potassium,  sodium, total  
bilirubin,  total protein, urea  nitrogen. 
 
6.4.4.3. Urinalysis  
A midstream  urine  sample  will be obtained, in  order to avoid contamination with  epithelial  cells 
and sediments,  and allow  proper  assessments,  and a standard,  semi-quantitative  dipstick  
performed to evaluate for common  urinary tract conditions. Urine dipstick  will include  
leukocytes, nitrites,  urobilinogen,  protein,  pH, blood (erythrocytes),  specific gravity, ketone, 
bilirubin  and glucose.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  27 of 47  6.4.4.4. Serology  
Subjects  will be assessed  for HIV,  Hepatitis  B surface antigen, and Hepatitis  C antibody results  
during screening.  
 
6.4.4.5. Pregnancy  testing  
A serum  beta- hCG pregnancy  test will be performed at screening  for females of childbearing 
potential.  Urine pregnancy testing will be performed for women  of childbearing potential within  
24 hours  prior  to the administration  of a radioligand  using a standard  kit. 
 
6.4.5. Electrocardiogram  (ECG)  
A standard  12 lead ECG  will be performed. Interpretation  of the tracing  must  be made  by a 
qualified  physician and documented on the  ECG  section  of the case report form  (CRF).  Each  
ECG tracing  should be labeled  with:  
Study number  
Subject  NDOB (Name Date of Birth) code  
Subject  number  
Date 
Time  
All ECG tracings  will be kept in the source  documents  at the study  site. Only  clinically  
significant  abnormalities  will be reported on this page. Clinically  significant  abnormalities  
should also be recorded as relevant  medical  history/current  medical  condition. 
The ECG parameters to be reported in  the database  will include:  
Date and time  of ECG  
Heart  rate 
PR interval 
QT interval 
QTc interval  
QTcF  interval 
QRS  duration 
The overall  interpretation  will be collected  with a Yes/No  statement  to confirm  if any clinically  
significant  abnormalities  are present  which  need to be specified  further.  
Original ECG  tracings , appropriately  signed, will be archived  at study  site. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  28 of 47  7. SAFETY MONITORING  
7.1. Adverse  Events 
Collection  of AEs will commence from  the time the subject  signs  the informed consent  to 
participate  in the study  and continue  until the subject  discontinues study  participation  (eg, screen  
failure,  study  withdrawal,  or study completion  [ie, Follow -up Phone Call]).  
 
7.1.1. AE Definition  
An AE is the appearance  or worsening of any undesirable sign, symptom,  or medical  condition, 
even if the event  is not considered to be related  to study  drug. Study drug  includes  the 
investigational drug under  evaluation during any phase of the study.  Medical  conditions/diseases 
present  before  starting  study  drug are only considered  AEs if they worsen  after  starting  study  
drug.  Abnormal  laboratory  values  or test results  constitute  AEs only if they induce clinical  signs  
or symptoms,  are considered clinically  significant,  or require  therapy. 
The occurrence of AEs should be sought  by non- directive  questioning of the subject  at each visit 
during the study. AEs also may be detected  when  they are volunteered by the  subject  during or 
between  visits  or through physical  examination,  laboratory test, or other assessments.  All AEs 
must  be recorded on the  Adverse  Event Form  with information  regarding the intensity, 
relationship  to study drug (imaging  ligand), relationship  to study  procedures,  duration and 
whether  it meets the criteria  as a SAE.  
The World  Health  Org anization  (WHO)  toxicity grading scale (see Section  12) will be used for 
assessing  AE severity.  Table  2 will be used for assessing  severity  for AEs that are not 
specifically  listed  in the WHO  toxicity grading scale.  
Table 2: Grading of AEs 
 
Grade  Intensity  
1 An AE that is mild and transient  (<48  hours).  No treatment  or therapeutic  
intervention  is required.  
2 An AE that is moderate.  There  is a mild to moderate  limitation  in activity.  Some  
assistance  may be needed.  No or minimal  therapeutic  intervention  is required.  
3 An AE that is severe.  There  is a marked  limitation  in activity,  and some  
assistance is usually  required.  Medical  intervention and/or  therapy is required.  
Hospitalization  is possible.  
4 An AE that is life-threatening.  There  is an extreme  limitation  in activity,  and 
significant  assistance is required. Significant medical  intervention and/or  therapy  
is required,  and hospitalization  or hospice  care is probable.  
 
7.1.2. SAE Definition  
An SAE  is defined  as an event  which:  
● is fatal or life-threatening  
● constitutes a congenital  anomaly/birth  defect  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  29 of 47  ● results  in persistent  or significant incapacity  or substantial  disruption of the ability  to conduct  
normal  life functions 
● is medically  significant,  ie, defined as an event  that jeopardizes  the subject  or may require  
medical  or surgical  intervention  to prevent  one of the outcomes  listed  above  
● requires  in-patient  hospitalization  or prolongation  of existing  hospitalization, unless  
hospitalization  is for: 
o routine  treatment  or monitoring  of the studied  indication,  not associated  with any 
deterioration  in condition 
o elective or pre-planned  treatment  for a preexisting  condition that is unrelated  to the 
indication  under  study  and has  not worsened since  the start of study drug 
 
7.1.3. Adverse Events  of Special  Interest  Definition  
Adverse  events of special  interest  (AESI)  are required  to be reported by the  investigator  to the 
Sponsor  immediately  (ie, no more  than 24 hours  after learning of the event;  see Section  7.2 for  
reporting  instructions).   AESI  for this study  are as follows:  
● Cases of potential drug-induced liver injury  that include  an elevated ALT  or AST  in 
combination  with either an elevated bilirubin  or clinical  jaundice,  as defined  by Hy's Law 
The finding  of an elevated ALT  or AST  (> 3 ULN)  in combination with either  an 
elevated total bilirubin  (2  ULN)  or clinical  jaundice  in the absence of cholestasis or other  
causes of hyperbilirubinemia  is considered  to be an indicator of severe liver injury  (as 
defined by Hy's Law).  Therefore, investigators  must  report as an AE the occurrence  of 
either  of the following:  
● Treatment -emerge nt ALT  or AST  > 3x ULN in combination with total bilirubin  
>2 x ULN 
● Treatment -emergent  ALT  or AST  > 3 x ULN in combination  with clinical  
jaundice  
The most  appropriate  diagnosis  or (if a diagnosis  cannot  be established)  the abnormal  
laboratory  values should  be recorded on the  Adverse  Event eCRF  and reported to the 
Sponsor  immediately  (ie, no more  than 24 hours after learning  of the event),  either  as a 
SAE  or an AESI.  
● Suspected transmission  of an infectious  agent  by the  study drug, as defined below   
Any organism, virus,  or infectious  particle  (eg, prion protein  transmitting  transmissible  
spongiform  encephalopathy), pathogenic  or non-pathogenic, is considered an infectious  
agent. A transmission  of an infectious  agent  may be suspected from  clinical  symptoms  or 
laboratory  findings  that indicate  an infection  in a subject  exposed  to a medicinal  product. 
This term applies only when a contamination of the study drug is suspected.  
 
7.1.4. Cases of Accidental  Overdose or Medication  Error 
Accidental  overdose and medication error (hereafter  collectively  referred  to as "special  
situations"),  are defined as follows:  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  30 of 47  ● Accidental  overdose:  accidental  administration  of a drug in a quantity that is higher  than the 
assigned  dose 
● Medication  error:   accidental  deviation in  the administration  of a drug 
o In some  cases,  a medication  error may be intercepted prior to administration  of 
the drug.  
Special  situations  are not in themselves AEs but may result  in adverse events.  Each  AE 
associated  with a special  situation  should be recorded separately  on the  Adverse Event eCRF.  If 
the associated  adverse event  fulfills  seriousness criteria,  the event  should be reported to  the 
Sponsor  immediately  (ie, no more  than 24 hours  after learning of the event;  see Section  7.2). For 
[18F]GTP1,  adverse events associated  with special  situations  should be recorded as described  
below  for each situation:  
● Accidental  overdose:  Enter the adverse event  term.  Check the  "Accidental  overdose" and 
"Medication  error"  boxes. 
● Medication  error that does  not qualify as an overdose: Enter  the adverse event  term.  Check  
the "Medication  error" box. 
● Medication  error that qualifies  as an overdose: Enter  the adverse event  term.  Check the  
"Accidental  overdose" and "Medication error"  boxes. 
In addition,  all special  situations  associated  with  [18F]GTP1,  regardless of whether  they result  in 
an adverse event, should be recorded on the  Adverse  Event  eCRF  as described  below:  
● Accidental  overdos e: Enter  the drug name  and "accidental  overdose" as the event  term.  
Check the  "Accidental  overdose" and "Medication  error"  boxes. 
● Medication  error that does  not qualify as an overdose: Enter  the name  of the drug 
administered  and a description  of the error (eg, wrong dose  administered,  wrong dosing 
schedule,  incorrect route of administration,  wrong drug,  expired drug administered)  as the 
event  term.  Check the  "Medication  error"  box. 
● Medication  error that qualifies  as an overdose: Enter  the drug name  and "accidental  
overdose" as the event  term.  Check the  "Accidental  overdose" and "Medication  error" boxes. 
Enter  a description  of the error in the additional  case details.  
● Intercepted  medication  error: Enter the drug name  and "intercepted  medication  error"  as the 
event  term.  Check the  "Medication  error"  box. Enter  a description  of the error in the 
additional  case details.  
As an example, an accidental  overdose that resulted  in a headache would require  two entries  on 
the Adverse  Event eCRF,  one entry to  report  the accidental  overdose and one entry to  report  the 
headache.  The "Accidental  overdose" and "Medication  error" boxes  would need to  be checked  
for both entries.  
 
7.1.5. Treatment  of AEs 
All AEs should be treated  appropriately.  Treatment  may include  one or more  of the following:  no 
action  taken (ie, further  observation only);  study drug dosage  adjusted/temporarily  interrupted; 
study  drug permanently discontinued due to this AE; concomitant  medication  given;  non-drug 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  31 of 47  therapy given;  subject  hospitalized/subject’s  hospital ization  prolonged. The  action  taken to  treat 
the AE should be recorded on the  Adverse  Event Form.  
Once  an AE is detected,  it should be followed until its resolution  to baseline  grade or better,  or 
until it is judged to be stable  or permanent  by the  investigator, or the participant  withdraws  
consent. Assessment  should be made  at each visit  (or more  frequently, if necessary)  of any 
changes  in severity,  the suspected relationship  to the study  drug, the interventions  required  to 
treat it, and the  outcome.  
Information  about  potential risks  of the investigational  drug will be included in  the subject’s 
informed  consent  and should be discussed with the subject  as part of the informed  consent  
signing and during the  study  as needed. 
 
7.1.6. Relationship of AEs to the Study  Drug  
The Investigator will document his/her  opinion of the relationship  of the AE to treatment  with 
the study drug (Table  3). 
Table 3: Relationship  of AEs to Study  Drug  
 
Relationship Description  
Yes A reaction  that follows  a reasonable  temporal  sequence  from  administration  of the 
drug or in which  the drug level  has been  established  in body  fluids  or tissue;  that 
follows  a known or expected  response  pattern  to the suspected  drug;  and that is 
confirmed  by improvement  on stopping or reducing the dosage  of the drug,  and 
reappearance of the reaction  on repeated  exposure.  
No An AE will be considered  related,  unless  it f ulfills  the criteria  specified  below:  
Evidence  exists that the AE has a cause  other  than [18F]GTP1  (eg, preexisting  
medical  condition,  underlying disease,  intercurrent illness, or concomitant  
medication).  AND/OR  The AE does not have  a plausible  temporal  relationship  
with [18F]GTP1  administration.  
 
7.2. Serious  Adverse Event  and Adverse  Event  of Special  Interest 
Reporting 
To ensure  subject  safety,  every  SAE  and AESI,  regardless of suspected causality,  occurring after  
the subject  has provided informed  consent  and until the subject  has completed  the study  must  be 
reported to  the study sponsor  within 24 hours  of learning of its occurrence.  
SAEs  that occur  later than the  Follow -up Phone Call will not require  reporting  unless  the 
Investigator believes  the event(s)  were  related  to either  the investigational study  drug or study 
procedures. 
Recurrent  episodes,  complications,  or progression  of the initial SAE/AESI  must  be reported as  
follow -up to  the original  episode, regardless of when the event  occurs.  This report  must  be 
submitted within 24 hours  of the Investigator receiving  the follow-up information. An 
SAE/AESI  that is considered completely  unrelated  to a previously reported one should  be 
reported separately  as a new event. New signs  or symptoms  or a change  in the diagnosis, 
significant  new diagnostic test results,  change  in the event’s  outcome,  including recovery,  
additional  information  on the  clinical  course  of the event  should also be submitted immediately.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  32 of 47  All SAE/AESIs,  regardless of causality,  will be reviewed  by the  study sponsor.  
 
7.3. Methods for Capturing and Assessing  Safety Parameters  
The investigator is responsible  for ensuring  that all adverse events (see Section  7.1.1for 
definition) are recorded on the  Adverse  Event  eCRF and reported to  the Sponsor  in accordance 
with instructions  provided in  this section  and in  Section  7.2 and 7.4. For each adverse event  
recorded on the  Adverse  Event eCRF,  the investigator  will make  an assessment  of seriousness  
(see Section  7.1.2 for seriousness  criteria),  severity  (see Section  7.1.1),  and causality  (see Section  
7.1.6).  
 
7.4. Procedures  for Recording Adverse Events 
 
7.4.1. Diagnosis  versus Signs  and Symptoms  
A diagnosis  (if known)  should be recorded on the  Adverse  Event eCRF  rather  than individual 
signs  and symptoms  (eg, record  only liver failure  or hepatitis  rather  than jaundice, asterixis,  and 
elevated transaminases).  However, if  a constellation  of signs  and/or symptoms  cannot  be 
medically  characterized  as a single  diagnosis  or syndrome  at the time of reporting, each 
individual event  should be recorded on the  Adverse  Event  eCRF.  If a diagnosis  is subsequently 
established,  all previously reported adverse events based  on signs  and symptoms  should be 
nullified and replaced  by one adverse  event  report  based  on the  single  diagnosis, with  a starting  
date that corresponds  to the starting  date of the first symptom of the eventual  diagnosis. 
 
7.4.2. Adverse Events  That  are Secondary  to Other  Events  
In general, adverse events that are secondary to  other  events  (e.g., cascade events or clinical 
sequelae)  should be identified  by their  primary  cause,  with  the exception of severe or serious  
secondary  events. A medically  significant  secondary  adverse  event  that is separated  in time  from  
the initiating  event  should be recorded as an independent  event  on the  Adverse Event  eCRF.  
 
7.4.3. Deaths  
All deaths  that occur  during the  protocol -specified  adverse event  reporting  period  (see Section  
7.2), regardless of relationship  to study  drug, must  be recorded on the  Adverse  Event eCRF  and 
immediately  reported. The event  or condition that caused  or contributed to  the fatal outcome  
should be recorded as  the single  medical  concept  on the  Adverse  Event  eCRF.  
 
7.5. Post-Study Adverse Events:  
If the investigator  becomes aware of any serious  adverse  event  that occurs  after  the end of the 
adverse event  reporting  period  (defined as within 4 days  (± 2 days)  post-injection  of [18F]GTP1),  
if the event  is believed  to be related  to prior study  drug treatment.  The investigator  should report 
these events directly  to the Sponsor  or its designee, by scanning  and emailing  the paper  Clinical 
Trial Adverse Event/Special  Situations  Form  using the email  address provided below:  
Email  address:  welwyn.pd s-pc@roche.com  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  33 of 47  8. DATA REVIEW  AND  DATABASE MANAGEMENT  
8.1. Site Monitoring  
During  the study,  a contracted  clinical  research  associate (monitor) will visit the site regularly  to 
check  the completeness of subject  records,  the accuracy  of data,  the adherence to the protocol  
and to  GCP,  the progress  of enrollment, and to  ensure  that study  drug is being stored,  dispensed,  
and accounted  for according to  specifications.  Key study personnel  must  be available  to assist  
the contracted  monitor  during these visits.  
The Investigator will maintain  source  documents  for each subject  in the study, consisting of case 
and visit  notes containing demographic  and medical  information, laboratory  data,  ECGs,  and the 
results  of any other  tests or assessments.  All information  in the database  must  be traceable to 
these source  documents  in the subject's file. The Investigator must  also keep the original 
informed  consent  form  signed by the subject  (a signed copy is  given to the subject).  
The Investigator will give the monitor  access to all relevant  source documents  to confirm  their 
consistency  with the database  entries.  Monitoring  standards  require  full verification  for the 
presence of informed consent, adherence to the inclusion/exclusion criteria,  documentation of 
SAEs,  and the recording  of data that will be used for all primary  and safety  variables.  Additional  
checks of the consistency  of the source  data with the database are performed according to  the 
study- specific monitoring  plan. No information  in source  documents  about  the identity  of the 
subjects will be disclosed. 
 
8.2. Database  Management and Quality Control  
Designated Investigator staff must  enter  the information  required  by the  protocol  into the study- 
specific database.  
Subsequently, the  entered data  are systematically  checked  by Quality  Assurance (QA)  and data  
management  staff,  including 100% verification  with source  documentation. Errors  or omissions  
are reconciled with the investigational  site for resolution. Quality  checking  audits  of all key 
safety  and efficacy data in the database  are made  prior to locking the database.  
 
9. DATA  ANALYSIS  
9.1. Subject  Demographics  and Other Baseline Characteristics  
All data for background and demographic  variables will be listed. Summary  statistics  will be 
provided for these parameters by subject.  Relevant  medical  history, current  medical  conditions, 
results  of laboratory  screens,  drug tests,  and any other relevant  information  will be listed  by 
subject.  
 
9.2. Imaging Analysis  and Statistics  
Whole -body  tomographic  PET images  created on the  PET camera will be transferred  to a 
dedicated  PMOD  (software  for biomedical  image  quantification)  workstation and reviewed  
visually  for assessment  of body organ distribution  of radioactivity.  Manually  delineated  dynamic  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  34 of 47  VOIs  will be placed  on the  visually  identified  source organs  and subsequently used  for all the 
study  PET frames.  Activity  within these  VOIs  is expressed  in unit of total radioactivity.  
Radioactivity will be corrected  for body  attenuation, but not for decay,  and time -activity  curves  
(TACs)  will be generated for each source  organ. Following  the last imaging  time point  residual  
radioactivity  will be assumed  to undergo physical  decay  only. Total  number  of disintegrations  
(ie, kinetic values  or residence times)  will be determined for each source  organ either  directly  as 
the area under  the curve  of each TAC,  or from  modeling of acquired TACs  in certain  source  
organs  (eg, gallbladder emptying, urinary bladder  voiding, and GI tract modeling). These  data 
will be utilized  in the MIRD  calculations of target  organ specific radiation  absorbed dose with 
correction  from  urine  assays and standard  GI kinetic models  (ICRP  2006) in Organ  Level  
Internal Dose  Assessment  (OLINDA)  (Stabin et al., 2005).  Standard MIRD  assumptions will be 
incorporated  in dosimetry  models  for determination  of radiation  absorbed doses  in target  organs  
and whole-body ( Harrison  et al. 2015, ICRP  2007 ). 
For whole-body biodistribution, the  following parameters will be evaluated: 
● Total  source  organ counts  based  on an  individualized VOI template  
● Source  organ upta ke and washout with calculation  of the total number  of disintegrations  (or 
residence time) using the area under  the time-activity  curve divided by the injected  dose of 
radiopharmaceutical  
● Radiation  absorbed dose estimates based  on the  MIRD methodology utilizing  urine  data in 
the model  for increased  accuracy  of urinary  bladder  wall dose 
● The ICRP  100 human  alimentary  tract (HAT)  model  will be applied to compute  residence 
times  in the small  intestine,  lower  and upper  large  intestine  
Descriptive  statistics  will be applied to describe biodistribution  of [18F]GTP1 by organ.  
 
9.3. Safety Analysis  and Statistics  
Safety  will be evaluated by the  following:  
● Incidence  and severity  of AEs 
● Results from measurements  of vital signs  
● Results from measurements  of ECGs  
● Physical  evaluation  
● Results from measurements  for parameters of clinical  laboratory  tests (hematology, clinical  
chemistry, and urinalysis)  
All vital signs, ECG,  laboratory  and AE data will be listed  by subject  and visit/time  and, if 
ranges  are available,  abnormalities  will be flagged and brought  to the Investigator’s  attention  for 
review.  Summary  statistics  will be provided by visit/time.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  35 of 47  9.4. Sample  Size 
The sample size for this study  was determined by practical  considerations  and is  not based  on 
statistical power  calculations.  Up to 6 evaluable  subjects  (with at least 1 male  and 1 female)  will 
complete this study.  
While  the sample  size is small,  this should be adequate  to determine  biodistribution and  
dosimetry calculations  of [18F]GTP1  in Japanese subjects.  
 
10. REGULATORY AND ETHICAL  CONSIDERATIONS  
10.1.  Regulatory and Ethical  Compliance 
This clinical study was designed and shall be implemented  and reported in accordance with the 
ICH E6Guidelines  for GCP,  with  applicable  local  regulations, and with  the ethical  principles  laid 
down in the Declaration  of Helsinki.  
 
10.2.  Informed Consent Procedures  
Eligible  subjects may only be included in the study  after providing written  (witnessed,  where  
required by law  or regulation),  IRB approved informed  consent. Informed consent  must  be 
obtained before conducting any study- specific procedures  (ie, all of the procedures  described  in 
the protocol). The  process of obtaining informed  consent should be documented in the subject  
source  documents. 
 
10.3.  Confidentiality  
Participants  will be identified  by a unique  number  assigned  during screening  and participant 
names  will be known only to the Investigators  and designated  study  staff.  Representatives from  
the FDA will have access to the medical  records  connected  to this study.  Study records  will be 
kept confidential to the extent provided by law.  Name  or other  identifying data will not be used 
in any report  or publication of this study. The data from  this study will be maintained  for a 
minimum  of ten years.  
 
10.4.  Responsibilities of the Investigator  and IRB 
The protocol  and the  proposed informed  consent  form must  be reviewed  and approved by a 
properly constituted  IRB before study start.  A signed and dated  statement  that the protocol and 
informed  consent  have been approved by the  IRB must  be present  before study  initiation.  Prior  to 
study  start,  the Investigator is required  to sign a protocol signature  page confirming his/her  
agreement  to conduct  the study  in accordance with these  documents  and all  of the instructions  
and procedures  found in this protocol  and to  give access to all relevant  data and records  to the 
contracted  monitor,  auditors, IRB,  and regulatory authorities  as required.  If an inspection of the 
clinical  site is requested by a regulatory authority, the  Investigator must  inform  the study  sponsor  
immediately  that this request  has been made.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  36 of 47  11. REFERENCES  
Arriagada  PV, Growdon  JH, Hedley -Whyte  ET, Hyman  BT. 1992. Neurofibrillary  tangles but 
not senile  plaques  parallel  duration and severity  of Alzheimer’s  disease.  Neurology 42 (3  
Pt):631 -9. 
Bohórquez S, Marik  J, Ogasawara A, Tinianow  JN, Gill HS, Barret  O, Tamagnan G, Alagille  E, 
Ayalon G, Manser  P, Bengtsson T, Ward  M, Willaims  SP, Kerchner  GA, Seibyl  JP, Marek  K, 
Weimer  RM. 2019. [18F]GTP1  (Genentech  Probe  1), a radioligand for detecting  neurofibrillary  
tangle  tau pathology in  Alzheimer's disease.  Eur J Nucl  Med Mol Imaging  46:2077-2089 
Churcher, I. 2006. Tau  therapeutic  strategies for the treatm ent of Alzheimer’s  disease.  Curr Top 
Med Chem  6(6):579- 95. 
Clark  CM, Schneider JA, Bedell  BJ, Beach  TG, Bilker WB, Mintun MA,  Pontecorvo MJ, Hefti  
F, Carpenter AP, Flitter ML, Krautkramer J, Kung HF, Coleman  RE, Doraiswamy  PM, 
Fleisher  AS, Sabbagh MN,  Sadowsky CH, Reiman  EP, Zehntner SP, Skovronsky DM, AV45 - 
07 Study Group. 2011. Use of florbetapir- PET for imaging  beta-amyloid pathology. JAMA 
305(3):275- 83. 
Cristy  M. 1981. Active bone marrow  distribution  as a function  of age in humans. Phys.Med.Biol.  
May;26(3):389- 400. 
Delaere P, Duyckaerts  C, Brion  JP, Poulain  V, Hauw JJ. 1989. Tau,  paired  helical  filaments  and 
amyloid  in the neocortex:  a morphometric  study  of 15 cases with graded  intellectual status  in 
aging and senile  dementia of Alzheimer  type. Acta  Neuropathologica  77:645- 53. 
Dickson TC,  Saunder  HL, Vickers JC. 1997. Relationship between  apolipoprotein E and the  
amyloid  deposits and dystrophic neuritis  of Alzheimer’s disease.  NeuropathAppl Neurobiol  
(23):483- 491. 
Duyckaerts C, Brion  JP, Hauw JJ, Flament -Durand J. 1987. Quantitative  assessment  of the 
density  of neurofibrillary  tangles  and senile plaques  in senile  dementia of the Alzheimer  type. 
Comparison  of immunocytochemistry with a specific antibody and Bodian’s protargol  method. 
Acta Neuropathologica  73:167- 70. 
Duyckaerts C, Delare P, Hauw JJ, Abbamondi-Pinto AL,  Sorbi  S, Allen  I, et al. 1990. Rating of 
the lesions in senile  dementia of the Alzheimer  type:  concordance between  laboratories.  A 
European multicenter  study  under  the auspices of EURAGE.  J Neurol  Sci 97:295- 323. 
Grundke  II, Iqbal  K, Tung  YC, Quinlan M, Wisniewski  HM, Binder  LI. 1986. Abnormal  
phosphorylation of the microtubule -associated  protein  tau (tau)  in Alzheimer  cytoskeletal  
pathology. Proc Natl  Acad  Sci USA 83:4913- 7. 
Harrison  J. 2015. Overview  of ICRP  Committee  2 'Doses from Radiation Exposure'. Ann.ICRP  
Jun;44(1 Suppl):15- 23. 
International  Commission  on Radiological  Protections. 2006. Human  alimentary  tract model  for 
radiological  protection. ICRP  Publication  100. A report  of The International Commission  on 
Radiological  Protection. Ann ICRP.36(1 -2):25- 327. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  37 of 47  International  Commission  on Radiological  Protections.  2007. The 2007 Recommendations of the 
International  Commission  on Radiological  Protection.  ICRP  publication 103. Ann. ICRP;37(2 - 
4):1-332. 
Hyman  BT, Phelps  CH, Beach  TG, et al. 2012. National Institute  on Aging- Alzheimer’s 
Associated guidelines  for the neuropathologic  assessment  of Alzheimer’s  disease.  Alzheimers 
Dement  8(1):1- 13. 
Klunk WE, Engler  H, Nordberg A, Wang  Y, Blomquist  G, Holt DP, et al. 2004a. Imaging brain 
amyloid  in Alzheimer’s  disease with Pittsburgh Compound-B. Ann Neurol  55:306- 19. 
Klunk WE, Lopresti  BJ, Ikonomovic  MD, Lefterov  IM, Koldamova RP, Abrahamson EE, et al. 
2004b. Binding of the positron emission  tomography tracer  Pittsburgh compound-B reflects 
the amount  of amyloid  beta in Alzheimer’s disease brain but not in transgenic  mouse  brain.  J 
Neurosci  25:10598- 606. 
Kosik  KS, Joachim  CT, Selkoe DJ. 1986. Microtubule -associated  protein  tau (tau)  is a major  
antigenic  component  of paired  helical  filaments  in Alzheimer’s disease.  Proc  Natl Acad  Sci 
USA 83:4044- 8. 
Leinonen V,  Alafuzoff I, Aalto  S, Suotunen T,  Savolainen S, Nagren  K, et al. 2008. Assessment  
of beta-amyloid in a frontocortical brain  biopsy specimen  and by positron emission  
tomography with carbon 11- labeled  Pittsburgh Compound B.  Arch  Neurol  65(10):1304- 1309.  
McLean  CA,  Cherny RA,  Fraser  FW, Fuller  SJ, Smith  MJ, Beyreuther K, et al. 1999. Soluble  
pool of Abeta  amyloid  determinant  of severity  of neurodegeneration in  Alzheimer’s disease.  
Annals  Neurol  46:860- 6. 
Ruiqig N, Gilberg  PG, Ber gfors  A, Marutle  A, Nordberg A.  2013. Amyloid  tracers detect  
multiple  binding sites in Alzheimer’s  disease brain  tissue.  Brain  136:2217- 2227.  
Sojkova  J, Driscoll I , Iacono D , Zhou Y , Codispoti  KE, Kraut  MA, Ferrucci  L, Pletnikova  O, 
Mathis CA, Klunk WE, O'Brien  RJ, Wong DF, Troncoso JC, Resnick  SM. 2011. In  vivo 
fibrillar beta-amyloid detected  using  [11C]PiB  positron emission  tomography and 
neuropathologic  assessment  in older adults.  Arch  Neurol  68(2):  232-40. 
Stephens A, Barthel  H, Ishii  K, Takao  M, Akatsu  H, Murayama  S, Rowe  C, Koglin N, Catafau  
A, Schulz -Schaeffer  W, Sabbagh M,  Sabri  O, Seibyl  J. 2014. A  negative  florbetaben  PET scan 
reliably  excludes amyloid  pathology as confirmed  by histopathology. Alzheimer’s  & Dementia  
10(4 Suppl)  P131. 
Stabin MG,  Sparks  RB, Crowe  E. 2005. OLINDA/EXM:  the second-generation personal  
computer  software for internal dose assessment  in nuclear  medicine. J.Nucl.Med. 46(6):1023- 
7. 
Wood JC, Mirra  SS, Polock MJ, Binder  LI. 1986. Neurofibrillary  tangles  of Alzheimer’s  disease 
share antigenic determinants  with the axonal  microtubules -associated  protein  tau (tau).  Proc 
Natl Acad  Sci USA 83:4040- 3. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  38 of 47  12. APPENDIX  1 – W ORLD  HEALTH  ORGANIZATION TOXICITY  GRADING  
SCALE  
WHO  Toxicity  Grading Scale for determining  the severity  of AEs 
 
ITEM  Grade  1 Toxicity  Grade  2 Toxicity  Grade  3 Toxicity  Grade  4 Toxicity  
HEMATOLOGY  
Hemoglobin  9.5 - 10.5 gm/Dl  8.0 - 9.4 gm/DI  6.5 - 7.9 gm/DI  <6.5  gm/DI  
Absolute  Neutrophil  
Count  1000- 1500/mm3
 750-999/mm  3
 500-749/mm3
 <500/mm3
 
Platelets  75000 -99000/mm3
 50000 -74999/mm3
 20000-49000/mm3
 <20000/mm3
 
Prothrombin  
Time  (PT)  1.01 - 1.25 x ULN  1.26-1.5 x ULN  1.51 - 3.0 x ULN  >3 x ULN  
Activated  Partial  
Thromboplastin  
(APPT)  1.01 - l.66 x ULN  1.67 - 2.33 x ULN  2.34-3 x ULN  >3 x ULN  
Fibrinogen  0.75 - 0.99  x LLN  0.50 - 0.74  x LLN  0.25 - 0.49  x LLN  <0.25xLLN  
Fibrin  Split Product  20-40 mcg/ml  41-50 mcg/ml  51-60 mcg/ml  > 60 mcg/ml  
Methemoglobin  5 -9 .9%  10.0 - 14.9 %  15.0- 19.9%  >20  % 
LIVER  ENZYMES  
AST  (SGOT)  l.25-2. 5  x ULN  2.6-5 x ULN  5.1-10 x ULN  > l0 x ULN  
ALT  (SGPT)  l.25-2. 5  x ULN  2.6-5 x ULN  5.1-10 x ULN  > l0 x ULN  
GGT  1.25 - 2.5 x ULN  1.6- 5 x ULN  5.1-10 x ULN  > l0 x ULN  
Alkaline  Phosphatase  1.25- 2. 5 x ULN  1.6- 5 x ULN  5.1-10 x ULN  > l0 x ULN  
Amylase  1.1 - 1.5 x ULN  1.6 - 2.0 x ULN  2.1-5.0 x ULN  >5.1  x ULN  
CHEMISTRIES  
Hyponatremia  130-135 mEq/L  123-129 mEq/L  116-122 mEq/L  < 116 or mental status  
changes  or seizures  
Hypernatremia  146- 150 mEq/L  151- 157 mEq/L  158-165 mEq/L  > 165 mEq/L or mental  
status  changes  or 
seizures  
Hypokalemia  3.0 - 3.4 mEq/L  2.5 - 2.9 mEq/L  2.0 - 2.4 mEq/L  
or intensive  
replacement  Rx 
required  or 
hospitalization  
required.  <2.0mEq/L  
or paresis  or ileus or 
life-threatening  
arrhythmia  
Hyperkalemia  5.6 - 6.0 mEq/L  6.1 - 6.5 mEq/L  6.6 - 7.0 mEq/1  > 7.0mEq/L  
or life-threatening  
arrhythmia  
Hypoglycemia  55-64 mg/dL  40-54 mg/dL  30-39mg/dL  <30 mg/dL or mental  
status  changes or coma  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  39 of 47  WHO  Toxicity Grading Scale for determining  the severity  of AEs,  continued 
 
ITEM  Grade  1 Toxicity  Grade  2 Toxicity  Grade  3 Toxicity  Grade  4 Toxicity  
CHEMISTRIES   (continued)  
 
Hyperglycemia 
(note  if fasting)   
116 - 160 mg/dL   
161- 250 mg/dL   
251 - 500 mg/dL   
> 500 mg/dL  or 
ketoacidosis    or 
seizures  
Hypocalcemia 
(corrected   for albumin)  8.4 - 7.8 mg/dL  7.7 - 7.0 mg/dL  6.9 - 6.1 mg/dL  < 6.1 mg/dL  
or life-threatening  
arrhythmia  or tetany  
Hypercalcemia 
(correct   for albumin)   
10.6 - 11.5 mg/dL  11.6 - 12.5 mg/dL  12.6 - 13.5 mg/dL  > 13.5 mg/dL   life- 
threatening arrhythmia  
Hypomagnesemia l.4- l.2mEq/L  1.1 - 0.9 mEq/L  0.8 - 0.6 mEq/L  < 0.6 mEq/L  or life- 
threatening 
arrhythmia  
Hypophosphatemia  2.0 - 2.4 mg/dL  1.5 -1.9 mg/dL  or 
replacement    Rx 
required  1.0-1.4 mg/dL  intensive 
Rx or hospitalization  
required  < 1.0 mg/dL  or life- 
threatening  arrhythmia  
Hyperbilirubinemia 1.1 -1.5 x ULN  1.6-2.5 x ULN  2.6-5 x ULN  >5 x ULN  
BUN  l.25-2.5  x ULN  2.6-5 x ULN  5.1- l0 x ULN  > l0 x ULN  
 
Creatinine   
1.1-l.5 x ULN  1.6-3.0 x ULN   
3.l-6 x ULN   
> 6 x ULN  or required  
dialysis  
URINALYSIS  
Proteinuria  1+or<  0.3%   or <3g/L  
or 200  mg - 1 gm 
loss/day  2 -3 + or 0.3 - 1.0%  or 
3-10 g/L 
1- 2 gm loss/day  4+or>  1.0%   or>  10 
g/L 
2-3 5 gm loss/day  nephrotic  syndrome or > 
3 5 gm loss/day  
Hematuria microscopic   only gross,  no clots gross+   clots obstructive    or required  
transfusion  
CARDIAC  DYSFUNCTION  
Cardiac  Rhythm   asymptomatic,  
transient   signs,  no 
Rx required  recurrent/persist  ent; 
No Rx required  requires   treatment  
Hypertension  transient   inc. >20mm;  
no Rx  recurrent,   chronic,   > 
20 mm, Rx required  requires   acute  Rx; No 
hospitalization  requires  
hospitalization  
Hypotension transient   orthostatic  
hypo tensi on,  No Rx  symptoms  correctable  
with oral  fluids  Rx  
requires   IV fluids;  no 
hospitalization  
required  requires  
hospitalization  
Pericarditis  minimal  effusion  mild/moderate  
asymptomatic  
effusion,   no Rx symptomatic  effusion;  
pain;  ECG  changes  tamponade;  
pericardiocentesis    or 
surgery   required  
 
Hemorrhage,   Blood 
Loss  
microscopic/occult   
mild,  no transfusion   
gross  blood  loss; 
1-2 units   transfused   
massive  blood loss; 
> 3 units   transfused  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  40 of 47  WHO  Toxicity Grading Scale for determining  the severity  of AEs,  continued 
 
ITEM  Grade  1 Toxicity  Grade  2 Toxicity  Grade  3 Toxicity  Grade  4 Toxicity  
RESPIRATORY  
Cough  transient - no Rx treatment   associated  
cough 
local Rx uncontrolled   
Bronchospasm,   Acute transient;   no Rx 
< 80% - 70% FEV 1 
(or peak flow)  requires   Rx 
normalizes   with 
bronchodilator;   FEV 1 
50% - 70% 
(or peak flow)  no normalization   with 
bronchodilator;  
FEV 1  25% - 50% 
(or peak flow 
retractions)  cyanosis:   FEV 1 
< 25% 
(or peak flow)  or 
intubated  
 
GASTROINTES  TINAL  
Stomatitis  mild  discomfort;   no 
limits  on activity  some  limits  on 
eating/drinking  eating/talking  very 
limited  requires   IV fluids  
 
Nausea mild  discomfort;  
maintains  reasonable  
intake  moderate   discomfort;  
intake  decreased  
significantly;  some  
activity  lin1ited  severe  discomfort;   no 
significant  intake;  
activities   limited  minimal  fluid  intake  
Vomiting transient   emesis  occasional/mode   rate 
vomiting  orthostatic  
hypotension  or IV 
fluids  required  hypotensive  shock  or 
hospitalization   required  
for IV fluid  therapy  
Constipation  Mild  moderate  severe  distensions  w/vomiting  
Diarrhea  transient   3-4 loose  
stools/day  5-7 loose stools/day  orthostatic  
hypo tensi on or 
> 7 loose  stools/  day 
or required   IV fluids  hypotensive  shock  or 
hospitalization  for IV 
fluid  therapy   required  
NEURO  & NEUROMUS  CUL  AR 
Neuro- Cerebellar  slight  incoordination  
dysdiadochokinesis  intention  tremor,  
dysmetria,   slurred  
speech;   nystagmus  locomotor  ataxia  incapacitated  
Mood  mild  anxiety  or 
depression  moderate   anxiety  or 
depression   and 
therapy  required  severe  anxiety  or 
depression   or mania;  
needs   assistance  acute  psychosis;  
incapacitated,   requires  
hospitalization  
 
Neuro Control  (ADL 
activities  of daily  
living) mild  difficulty  
concentrating;   no Rx; 
mild  
confusion/agitation;  
ADL  unaffected moderate 
confusion/agitation  
some  limitation  of 
ADL;  minima  l Rx severe confusion/agitation  
needs   assistance  for 
ADL;  therapy  
required  toxic  psychosis;  
hospitalization  
Muscle  Strength  subjective  weakness  
no objective 
symptoms/signs  mild  objective  
signs/symptoms no 
decrease  in function  objective  weakness  
function limited  paralysis  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  41 of 47  WHO  Toxicity Grading Scale for determining  the severity  of AEs,  continued 
 
ITEM  Grade  1 Toxicity  Grade  2 Toxicity  Grade  3 Toxicity  Grade  4 Toxicity  
OTHER  PARAMETE RS 
FEVER:  oral, >12 hours  37.7-38.5 C or 
100.0- 101.5 F 38.6-39.5 C or 
101.6- 102.9 F 39.6-40.5 C or 
103-105 F >40 C or 
>105 F 
Headache  mild,  no Rx therapy  transient, moderate,  Rx 
required  severe,  responds  to initial  
narcotic therapy  intractable;  required  repeated  
narcotic therapy  
Fatigue no decrease in ADL  normal  activity  
decreased  25-50% normal  activity  
decreased  >50%  can’t 
work  unable  to care for self 
Allergic  Reaction  pruritus  without  rash localized urticaria  generalized  urticaria;  
angioedema anaphylaxis  
Local  Reaction tenderness  or erythema  induration  < 10 cm or 
phlebitis  or inflammation  induration  > 10 cm or 
ulceration  necrosis  
 
Mucocutaneous  erythema;  pruritus   
diffuse,  maculopopular  
rash, dry desquamation   
vesiculation, moist  
desquamation,  or 
ulceration   
exfoliative  dermatitis,  
mucous  membrane  
involvement  or erythema,  
multiforme or  suspected 
Stevens -Johnson or necrosis  
requiring surgery 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  42 of 47  13. APPENDIX  2 – PROTOCOL  SUMMARY OF CHANGES , AMENDMENT 1 
 
Rationale:  
Updates  were  included to  clarify  that approved forms  of birth control are not prohibited  
prescription  medications.  
 
The following  amendments  were incorporated:  
 
Page  Section  17-Jan-2020,  v1.0 
WAS 21-Jan-2020,  v2.0 
IS 
1 Title Page,  
Header  V1.0,  17-Jan-2020  V2.0,  21-Jan-2020  
9,19 Synopsis,  
Exclusion 
Criteria  Use of any prescription  drugs,  herbal  
supplements, within four  weeks prior 
to initial dosing. Use of any prescription  drugs  (except  
approved forms  of birth control noted 
in Section  5.2.3) , herbal  supplements, 
within four weeks prior to initial 
dosing.  
21 Concomitant  
Treatment  Use of any prescription  drugs,  herbal  
supplements, within four (4) weeks 
prior to initial dosing, and/or OTC 
medication, dietary supplements  
(vitamins  included)  within two (2) 
weeks prior to initial dosing is  
prohibited. If needed  (ie, an incidental 
and limited  need), acetaminophen is 
acceptable,  but must  be documented 
as a concomitant  
medication/significant  non-drug 
therapy. Use of any prescription  drugs,  herbal  
supplements, within four (4) weeks 
prior to initial dosing, and/or OTC 
medication, dietary supplements  
(vitamins  included)  within two (2) 
weeks prior to initial dosing is 
prohibited. Approved forms  of 
prescription  birth control (hormonal  
contraceptives,  hormone -releasing  
intrauterine  d evices,  and copper  
intrauterine  d evices)  are not 
prohibited and will be d ocumented as  
a concomitant  med ication.  If needed  
(ie, an incidental and limited  need), 
acetaminophen  is acceptable,  but 
must  be documented as a concomitant  
medication/significant  non-drug 
therapy.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  43 of 47  14. APPENDIX  3 – PROTOCOL  SUMMARY OF CHANGES , AMENDMENT 2 
 
Rationale:  
Updates  were  included to  add information  on adverse events of special  interest,  special  situations  
(accidental  overdose or medication  error),  and methods  for capturing and assessing  safety.  
 
The following  amendments  were incorporated:  
 
Page  Section  21-Jan-2020,  v2.0 
WAS 09-July-2020,  v3.0 
IS 
1 Title Page,  
Header  V2.0,  21-Jan-2020  V3.0,  09-Jul-2020  
29 Section  
7.1.3 N/A Added  section  to define  adverse  
events of special  interest.  (see 
inserted  text below)  
29 Section  
7.1.4 N/A Added  section  to define  special  
situations,  cases of accidental  
overdose or medication  error.  (see 
inserted  text below)  
30 Section  
7.1.5 Once  an AE is detected,  it should be 
followed until its resolution or until it 
is judged to be permanent, and 
assessment  should be made  at each 
visit (or more  frequently, if  
necessary)  of any changes  in severity,  
the suspected relationship to the study  
drug,  the interventions  required  to 
treat it, and the  outcome.  
Information  about  common  side 
effects  already  known about  the 
investigational drug will be included 
in the subject’s informed  consent  and 
should be discussed with the subject  
during the study  as needed. Once  an AE is detected,  it should be 
followed until its resolution to 
baseline grade  or better,  or until it is 
judged to be stable or permanent  by 
the investigator,  or the participant 
withd  raws consent,. and a Assessment  
should be made  at each visit  (or more  
frequently, if necessary)  of any 
changes  in severity,  the suspected  
relationship  to the study  drug,  the 
interventions  required  to treat it, and 
the outcome. 
Information  about  potential risks 
common  sid e effects  alread  y known 
about  of the investigational drug will 
be included in  the subject’s informed 
consent  and should be discussed with 
the subject  as part of the informed  
consent  signing and during the  study 
as needed. 
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  44 of 47   
31 Section  7.2 7.2 Serious  Adverse Event  
Reporting  
To ensure  subject  safety,  every  SAE,  
regardless of suspected causality,  … 
Recurrent  episodes,  complications,  or 
progression  of the initial SAE  must  be 
reported  … An SAE  that is 
considered completely  unrelated  to a 
previously reported one should be 
reported  separately  as a new event. 
All SAEs,  regardless of causality,  will 
be reviewed  by the  study  sponsor.  7.2 Serious  Adverse Event  and 
Adverse Event  of Special  Interest  
Reporting  
To ensure  subject  safety,  every  SAE  
and AESI,  regardless of suspected  
causality,  … 
Recurrent  episodes,  complications,  or 
progression  of the initial SAE /AESI  
must  be reported  … An  SAE /AESI  
that is considered completely  
unrelated  to a previously  reported one 
should be reported separately  as a 
new event. New signs  or symptoms  or 
a change  in the d iagnosis,  significant  
new d iagnostic  test results,  change  in 
 t he event  ’s out come,  includ ing   
recovery, ad d itional information on 
the clinical  course of  the event  should  
also be submitted immed  iately.  
All SAE /AESI s, regardless of 
causality,  will be reviewed  by the  
study  sponsor.  
32 Section  7.3 N/A Added section  to define  methods  for 
capturing and assessing  safety  
parameters.  (see inserted  text below)  
32 Section  7.4 N/A Added section  to define  the 
procedures  for adverse event  
reporting. (see inserted  text below)  
32 Section  7.5 N/A Added section  to define  the 
procedures  for post-study adverse 
events. (see inserted  text below)  
 
 
 
Sections inserted  for Protocol  Amendment  2: 
 
Section  7.1.3. - Definition  of adverse events of special  interest  
Adverse  events of special  interest  (AESI)  are required  to be reported by the investigator  to the 
Sponsor  immediately  (ie, no more  than 24 hours  after  learning  of the event;  see Section  7.3 for 
reporting  instructions).   AESI  for this study  are as follows:  
Pr ot oc ol  N o.  G N 4 2 0 4 3  
V 3. 0  ; 0 9 -J ul -2 0 2 0  
C o nfi de ntial  Pa ge  4 5  of 4 7   • Cases  of p ote ntial dr u g-i n d uce d li ver  i nj ur y  t hat  i ncl u de  a n  ele vate d A L T  or A S T  i n  
c o m bi nati o n  wit h  eit her  a n  ele vate d bilir u bi n  or  cli nical  ja u n dice,  as  defi ne d  b y H y's La w  
• T he  fi n di n g  of a n  ele vate d A L T  or A S T  ( >  3 U L N)  i n  c o m bi nati o n  wit h  eit her  a n  ele vate d  
t ot al  bilir u bi n   ( 2  U L N)  or cli nical  ja u n dice  i n  t he  a bse nce  of c h olestasis  or ot her ca uses  of 
h y per bilir u bi ne mia  is c o nsi dere d  t o  be a n  i n dicat or of se vere  li ver  i nj ur y  (as  defi ne d  b y  H y's 
La w).  T heref ore,  i n vesti gat ors  m ust  re p ort  as  a n  A E t he  occ urre nce  of  eit her  of t h e  
f oll o wi n g:  
• Treat me nt -e mer ge nt  A L T  or A S T  > 3 x  U L N  i n  c o m bi nati o n  wit h  t ot al  bilir u bi n   > 2 x U L N  
• Treat me nt -e mer ge nt  A L T  or A S T  > 3 x U L N  i n  c o m bi nati o n  wit h  cli nical  ja u n dice  
• T he  m ost  a p pr o priate  dia g n osis  or (if  a dia g n osis  ca n n ot  be esta blis he d)  t he  a b n or mal  
la b orat or y  val ues  s h o ul d  be rec or de d o n t he  A d verse  E ve nt e C R F  a n d re p orte d  t o  t h e  
S p o ns or  i m me diatel y  (ie,  n o m ore  t ha n  2 4 h o urs  aft er  lear ni n g  of t h e  e ve nt),  eit her  as  a S A E  
or a n  A E SI.  
• S us pecte d tra ns missi o n   of a n  i nfecti o us  a ge nt b y t he  st u d y  dr u g,  as  defi ne d bel o w  
• A n y  or ga nis m,  vir us,  or i nfecti o us  particle  (e g,  pri o n  pr otei n  tra ns mitti n g  tra ns missi ble  
s p o n gif or m  e nce p hal o pat h y),  pat h o ge nic  or n o n -pat h o ge nic,  is c o nsi dere d  a n  i nfecti o us  
a ge nt.  A tra ns missi o n   of a n  i nfecti o us  a ge nt  ma y  be s us pecte d fr o m  cli nical  s y m pt o ms  or 
la b orat or y  fi n di n gs  t hat i n dicate  a n  i nfecti o n  i n  a s u bject  e x p ose d  t o  a me dici nal  pr o d uct.  
T his  ter m  a p plies  o nl y  w he n  a c o nta mi nati o n  of t he  st u d y  dr u g  is  s us pecte d.  
 
 
Secti o n  7. 1. 4.  - Defi niti o n  of c ases  of acci de nt al  o ver d ose  or  me dic ati o n  err or  
Acci de ntal  o ver d ose a n d me dicati o n  err or  ( hereafter  c ollecti vel y  referre d  t o  as  "s pecial  
sit uati o ns"),  are  defi ne d  as  f oll o ws:  
• Acci de ntal  o ver d ose:  acci de ntal  a d mi nistrati o n  of  a dr u g  i n  a q ua ntit y t hat is hi g her   t ha n t h e  
assi g ne d  d ose  
• Me dicati o n  err or:   acci de ntal  de viati o n i n  t he  a d mi nistrati o n  of a dr u g  
o  I n  s o me  cases,  a me dicati o n  err or  ma y  be i nterce pte d pri or  t o  a d mi nistrati o n  of 
t he  dr u g.  
S pecial  sit uati o ns  are  n ot i n  t he msel ves  A Es  b ut ma y  res ult  i n  a d verse  e ve nts.  Eac h  A E  
ass ociate d  wit h  a s pecial  sit uati o n  s h o ul d  be rec or de d se paratel y  o n t he  A d verse E ve nt e C R F.  If  
t he  ass ociate d  a d verse  e ve nt  f ulfills  seri o us ness  criteria,  t h e  e ve nt  s h o ul d  be re p orte d t o  t h e  
S p o ns or  i m me diatel y  (ie,  n o m ore  t ha n  2 4 h o urs aft er  lear ni n g  of t h e  e ve nt;  see  Secti o n  7. 2).  F or  
[1 8 F] G T P 1,  a d verse  e ve nts ass ociate d  wit h s pecial  sit uati o ns  s h o ul d  be rec or de d  as  descri be d  
bel o w  f or  eac h  sit uati o n:  
• Acci de ntal  o ver d ose:  E nt er t he  a d verse  e ve nt  ter m.  C hec k t h e  " Acci de ntal  o ver d ose" a n d  
" Me dicati o n  err or"  b o xes.  
• Me dicati o n  err or  t hat  d o es  n ot  q ualif y  as  a n  o ver d ose: E nter  t h e  a d verse  e ve nt  ter m.  C hec k  
t he  " Me dicati o n  err or"  b o x. 
Pr ot oc ol  N o.  G N 4 2 0 4 3  
V 3. 0  ; 0 9 -J ul -2 0 2 0  
C o nfi de ntial  Pa ge  4 6  of 4 7   • Me dicati o n  err or  t hat  q ualifies  as  a n  o ver d ose: E nt er  t he  a d verse e ve nt  ter m.  C hec k t h e  
" Acci de ntal  o ver d ose" a n d " Me dicati o n  err or"  b o xes.  
I n  a d diti o n,  all  s pecial  sit uati o ns  ass ociate d  wit h  [ 1 8 F] G T P 1,  re gar dless  of  w het her  t he y  res ult  i n  
a n a d verse  e ve nt, s h o ul d  be rec or de d o n t he  A d verse  E ve nt  e C R F  as  descri be d  bel o w:  
• Acci de ntal  o ver d ose: E nter t h e  dr u g  na me  a n d "acci de ntal  o ver d ose" as  t he  e ve nt  ter m.  
C hec k t he  " Acci de ntal  o ver d ose" a n d " Me dicati o n  err or"  b o xes.  
• Me dicati o n  err or  t hat  d o es  n ot  q ualif y  as  a n  o ver d ose: E nter  t h e  na me  of t h e  dr u g  
a d mi nistere d  a n d a descri pti o n  of t h e  err or  (e g,  wr o n g d ose  a d mi nistere d,  wr o n g d osi n g 
sc he d ule,  i nc orrect  r o ute of a d mi nistrati o n,  wr o n g dr u g,  e x pire d  dr u g  a d mi nistere d)  as  t h e  
e ve nt  ter m.  C hec k t he  " Me dicati o n  err or"  b o x. 
• Me dicati o n  err or  t hat  q ualifies  as  a n  o ver d ose: E nt er  t he  dr u g  na me  a n d  "acci de ntal  
o ver d ose" as  t he  e ve nt  ter m.  C hec k t h e  " Acci de ntal  o ver d ose" a n d " Me dicati o n  err or"  b o xes.  
E nt er  a descri pti o n  of t he  err or  i n  t h e  a d diti o nal  case details.  
• I nterce pt e d  me dicati o n  err or:  E nt er t h e  dr u g  na me  a n d "i nterce pte d  me dicati o n  err or"  as  t he  
e ve nt  ter m.  C hec k t he  " Me dicati o n  err or"  b o x. E nt er  a descri pti o n  of t he  err or  i n  t h e  
a d diti o nal  case  details.  
As  a n  e xa m ple,  a n  acci de ntal  o ver d ose t hat  res ulte d  i n  a hea dac he  w o ul d re q uire  t w o  e ntries  o n 
t he  A d verse  E ve nt e C R F,  o ne e ntr y t o  re p ort  t h e  acci de ntal  o ver d ose a n d o ne e ntr y t o  re p ort  t h e  
hea dac he.  T he  " Acci de ntal  o ver d ose" a n d " Me dicati o n  err or"  b o xes  w o ul d nee d t o  be c hec ke d  
f or  b ot h  e ntries.  
 
Secti o n  7. 3. – Defi niti o n  of met h o ds  f o r  c a pt uri n g  a n d  assessi n g  s afet y  p ar a meters  
T he  i n vesti gat or  is  res p o nsi ble  f or  e ns uri n g  t hat  all  a d verse  e ve nts  (see  Secti o n  7. 1. 1f or  
defi niti o n)  are  rec or de d o n t he  A d verse  E ve nt  e C R F a n d re p orte d t o  t he  S p o ns or  i n  acc or da nce  
wit h  i nstr ucti o ns  pr o vi de d i n  t his  secti o n  a n d i n  Secti o n  7. 2 a n d 7. 4. F or eac h  a d v ers e  e ve nt  
rec or de d o n t he  A d verse  E ve nt e C R F,  t he  i n vesti gat or  will  ma ke  a n  assess me nt   of seri o us ness  
(see  Secti o n  7. 1. 2 f or  seri o us ness  criteria),  se verit y  (see  Secti o n  7. 1. 1),  a n d ca usalit y  (see  Secti o n  
7. 1. 6).  
 
Secti o n  7. 4. – Defi ni n g  pr oce d ures f o r  rec or di n g  a d verse  e ve nts  
7. 4. 1.  Di a g n osis  vers us  Si g ns  a n d  S y m pt o ms  
A dia g n osis  (if  k n o w n)  s h o ul d  be rec or de d o n t h e  A d verse  E ve nt e C R F  rat her  t ha n i n di vi d ual 
si g ns  a n d s y m pt o ms  (e g,  rec or d  o nl y  li ver  fail ure  or he patitis  rat her  t ha n  ja u n dice,  asteri xis,  a n d  
ele vate d tra nsa mi nases).   H o we ver, if  a c o nstellati o n  of si g ns  a n d/ or s y m pt o ms  ca n n ot  be 
me dicall y  c haracterize d  as  a si n gle  dia g n osis  or s y n dr o me  at  t h e  ti me  of re p orti n g,  eac h  
i n di vi d ual e ve nt  s h o ul d  be rec or de d o n t he  A d verse  E ve nt  e C R F.  If  a dia g n osis  is  s u bse q ue ntl y  
esta blis he d,  all  pre vi o usl y  re p orte d a d verse  e ve nts  base d  o n si g ns  a n d s y m pt o ms  s h o ul d  be 
n ullifie d  a n d re place d   b y o ne a d verse  e ve nt  re p ort  base d  o n t he  si n gle  dia g n osis,  wit h  a starti n g  
d at e  t hat c orres p o n ds  t o  t h e  starti n g d at e  of t he  first  s y m pt o m of t h e  e ve nt ual  dia g n osis.  
Protocol  No. GN42043  
V3.0  ; 09-Jul-2020 
Confidential  Page  47 of 47  7.4.2. Adverse Events  That  are Secondary  to Other  Events  
In general, adverse events that are secondary to  other  events  (e.g., cascade events or clinical 
sequelae)  should be identified  by their  primary  cause,  with  the exception of severe or serious  
secondary  events. A medically  significant  secondary  adverse  event  that is separated  in time  from 
the initiating  event  should be recorded as an independent  event  on the  Adverse  Event  eCRF.  
7.4.3. Deaths  
All deaths  that occur  during the  protocol -specified  adverse event  reporting  period  (see Section  
7.2), regardless of relationship  to study  drug, must  be recorded on the  Adverse  Event eCRF  and 
immediately  reported. The event  or condition that caused  or contributed to  the fatal outcome  
should be recorded as  the single  medical  concept  on the  Adverse  Event  eCRF.  
 
Section  7.5. – Defining procedures for post-study  adverse events  
If the investigator  becomes aware of any serious  adverse event  that occurs  after  the end of the 
adverse event  reporting  period  (defined as within 4 (±  2 days)  post-injection  of [18F]GTP1),  if the 
event  is believed to be related  to prior  study  drug treatment. The investigator should report  these 
events directly  to the Sponsor  or its designee,  by scanning and emailing  the paper  Clinical Trial 
Adverse  Event/Special  Situations Form  using the email  address provided below:  
Email  address:  welwyn.pds-pc@roche.com  